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Abstract
Prostate cancer (PCa) is one of the most common cancers in males around the world. 
Prostate-specific antigen (PSA) is a serine protease that is secreted at high levels by 
prostate epithelial cells and most prostate cancer cells. It is thought that this enzyme is 
involved in prostate cancer cell invasion. This study aimed to test the effects of 
enzymatically active PSA and inactive forms of PSA on prostate cancer cell invasion. 
PSA is transcribed with a 17 amino acid secretory “pre” sequence and a 7 amino acid 
latency-conferring “pro” sequence. A deletion mutant lacking the “pro” region of the 
full-length preproPSA gene was used to create the prePSA gene, in the hopes that 
enzymatically active PSA would be formed upon cleavage of the “pre” sequence. Full 
length preproPSA cDNA and prePSA cDNA were each inserted into plasmids that 
allowed for inducible expression of the PSA genes under the control of the insect 
hormone derivative, ponasterone A (PonA). DU-145 subclones were created with the 
ability to inducibly produce preproPSA (DU-pERV3 C3 ppPSA) and prePSA (DU- 
pERV3 C3 prePSA). The growth properties, migratory abilities, and invasiveness of 
these cells were assayed. The same properties were tested with exogenous active PSA 
added to DU-145 cells. Exogenous PSA induced little change in growth, invasion or 
migration. However, there was a slight decrease in the invasion of DU-145 cells when 
using commercially isolated enzymatically active PSA. DU-pERV3 C3 ppPSA 
transfected cells showed increased invasion compared to control cells. Conversely, DU- 
pERV3 C3 prePSA transfected cells showed decreased invasion and migration compared 
to control cells. This study suggests that active PSA decreases the invasiveness of DU- 
145 cells, whereas the inactive zymogen form increases cellular invasion.
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Introduction
1 Prostate cancer
Prostate cancer (PCa) is one of the most frequent cancers to occur in men in North 
America and is a leading cause of cancer death in the United States \  It is estimated that 
in the US alone, there will be over 230,000 new cases of PCa and over 27,000 people will 
die due to the disease in 2006^. It is a disease of the elderly, and over 70% of PCa 
diagnosed in the US is in men over the age of sixty-five^. By the time it is diagnosed, 
about three out of every four men positive for PCa show signs of invasive or metastatic 
disease'*. Tumour metastasis and invasion is responsible for the majority of morbidity 
and mortality, and metastatic disease of the prostate is currently incurable^. An 
understanding of the biology of the development and progression of PCa is important in 
understanding the disease.
1.1 Prostate biology
The prostate is a walnut sized organ in the male through which the urethra passes. It is 
located inferior to the bladder and anterior to the rectum and is divided into three major 
zones: the peripheral zone, the central zone, and the transition zone®. The vas deferens 
and the seminal vesicles join the urethra in the prostate and this sexual gland functions to 
add secretions to seminal plasma to form an ejaculate^. These secretions contain acid 
phosphatases, zinc, magnesium, albumin, and prostate-specific antigen (PSA)*. 
Following ejaculation, the seminal fluid quickly forms a gel encasing the spermatozoa^. 
There is strong evidence that the function of the prostatic secretions is to aid in the lysis 
of this gel over time through the actions of proteases^.
13
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The interior structure of the prostate consists of branching acinar ducts that 
converge towards the urethra. The epithelial cells that line the ducts include secretory 
cells in contact with the lumen and basal cells which are thought to be precursors of 
secretory cells*®. Other cells present may include lymphocytes and stromal cells such as 
fibroblasts, and muscle cells*®. Both epithelial and stromal prostate cell growth and 
function is largely controlled by the androgen testosterone, which is mainly produced by 
the testis**. It is converted intracellularly to 5a-dihydrotestosterone (DHT) by the 
enzyme 5-a reductase’’*̂ . DHT is then available to bind to the cytoplasmic androgen 
receptor (AR), which translocates into the nucleus, where the complex acts as a 
transcriptional activator^. Other androgens can also bind to the AR and induce similar 
effects. The AR has been implicated in the upregulation of transcription genes involved 
in the cell cycle, such as cyclin-dependent kinases 2 (cdk2) and 4 (cdk4) -  both involved 
in advancing the cell cycle -  as well as upregulation of growth factors, such as 
keratinocyte growth factor (KGF)**. However, the activated AR complex also promotes 
differentiation in epithelial cells, and so plays a dual regulatory role on growth activation 
and inhibition*'*. In addition to the influence of androgens in prostate growth, 
differentiation and function are the effects of peptide growth factors as well as cytokines. 
Together they form a complex network of growth/inhibition interactions**. For example, 
epidermal growth factor (EGF) acts as a mitogen for epithelial prostate cells, whereas 
transforming growth factor p (TGF-p) acts as an antagonist for positive growth factors**. 
Furthermore, there are also complex interactions between different cell types in the 
prostate, as stromal cells produce androgen-induced growth factors (andromedins) that 
can affect epithelial cells*'*. During normal prostate growth, androgens such as
14
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testosterone function to suppress many andromedin-stimulating effects on epithelial cells, 
putting androgens at the forefront in control of growth and differentiation of these duct 
lining cells*'*.
1.2 Development of prostate cancer
Over 95% of prostate cancers originate from the epithelial cells that line the acinar ducts 
of the prostate*, and can thus be classified as adenocarcinomas*. More than 80% of 
cancers originate in the peripheral zone of the prostate*®, which constitutes about % of the 
volume of the prostate. This is clinically important, as it is the transition zone where 
most benign prostatic hyperplasia (BPH)* -  a common syndrome associated with an 
enlarged prostate -  arise, however, only a small fraction of cancers originate in the 
transition zone. One of the first signs of PCa is thought to be prostatic intraepithélial 
neoplasia (PIN)* .̂ PIN refers to morphological changes of epithelial cells in the acinar 
ducts that precede PCa, such as irregular cell spacing and nuclear enlargement**.
The initial molecular changes that are associated with PCa are less clear and 
appear to be heterogeneous in origin. Under normal conditions, effects of growth factors 
produced by the stromal cells on epithelial cells are kept in check by direct androgen 
stimulation of the epithelial cells. However, this process becomes dysregulated in 
prostate tumourigenesis, and PCa cell growth can be stimulated by the effects of both 
androgens and growth factors*'*. Upregulation of growth factor receptors and down 
regulation of the androgen receptor are common themes in PCa*'*. One common mutation 
suspected to be carcinogenic in the prostate is “loss-of-fimction” mutations in the 
glutathione S-transferase PI (GSTPl) protein -  an enzyme responsible for metabolizing 
reactive oxygen species*®. Another genetic alteration that may initiate PCa is a copy
15
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number increase of the c-Myc proto-oncoprotein, a transcriptional activator involved in 
cell proliferation and transformation*®. Amplification of c-Myc is seen in 40% of 
primary prostate cancers*®.
1.3 Prostate cancer progression and androgen independence 
PCa progresses in similar ways to many other adenocarcinomas. Briefly, the tumour 
attracts a blood supply, cells detach from the tumour and invade the surrounding tissue, 
and finally, tumour cells metastasize to distant organs*. Many genetic changes in PCa 
cells have been associated with cancer progression. Functional deletions of the 
phosphatase and tensin homologue (PTEN) protein -  an inhibitor of the 
phosphatidylinositol-3-kinase signalling pathway -  are frequent in late stage and 
metastatic prostate cancers*'*’*®, leading to increased invasiveness*®. Furthermore, 
deleterious mutations in the p53 sequence -  a tumour suppressor protein whose fimction 
is lost in numerous cancers -  are frequently observed in late stage tumours and in 
métastasés*®, most likely allowing for widespread unregulated changes in genomic DNA.
Androgen independence is another key factor in PCa progression. For PCa cells 
to extend their growth to regions outside of the prostate with lower concentrations of 
testosterone, they must reduce their dependence on this hormone for growth. As well, 
decreasing effects of androgens on PCa cells reduces their inhibitory and differentiation- 
inducing properties. There are multiple means by which PCa cells can become androgen 
independent; through hypersensitivity to androgens by increasing the amount of AR, 
mutations that allow the AR to recognize non-androgen steroids, or by using an 
alternative growth pathway that bypasses the androgen dependence through signalling 
cross-talk**. As one example, defects in autocrine production or changes in cellular
16
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response to TGF-p 1 can allow cells to proliferate in an uncontrolled manner regardless of 
androgen availability'*. Another specific means for PCa cells to become androgen 
independent is by upregulating the AR-binding protein CBP, which allows other steroids 
than androgens the activate the AR**. The evolved mechanisms to prevent the need for 
androgens are numerous and are a large obstacle in the development of new treatment 
options for PCa patients.
1.4 Screening and staging of prostate cancer
There are several methods to screen patients for PCa. Examination of the prostate can be 
done either by ultrasound or a digital rectal exam, where prostate enlargement is the main 
indicator for abnormality*. However, this method can confuse PCa with BPH, a non- 
malignant condition that is also associated with an enlarged prostate. In addition to direct 
examination, the level of PSA in the patient’s serum can be used as a diagnostic 
indicator. PSA is almost exclusively produced by the prostate, and measuring levels of 
this protein in the bloodstream can be predictive of cancer**. This method will be 
described at length in section 3.5.
Prostate biopsies are used to diagnose and grade prostate cancer. Tumours are 
graded using the Gleason score and staged using the TNM levels, each an indication of 
the progression of the tumour. The Gleason score uses the levels of differentiation of 
particular glandular patterns with low levels of differentiation correlating with higher 
Gleason scores and poorer prognosis*. TNM stages are common criteria used to stage 
cancers, and refer to the size, spread and aggressiveness of the tumour*.
17
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1.5 Treatment of prostate cancer
The treatment of a PCa patient depends largely on the stage, grade, and localization of the 
cancer. Localized PCa is much easier to treat than metastasized cancer. Prostatectomy is 
one option where the whole prostate gland is removed by surgery. It is most effective in 
patients with localized disease*. Radiation therapy is also an option, where an external 
ionizing radiation beam is used to irradiate and kill the cancerous cells without the 
removal of the prostate gland**. However, there is always the risk of adverse effects to 
non-cancerous cells when using ionizing radiation*'*.
Another method of PCa treatment is androgen deprivation. Since the growth of 
prostate epithelial cells is largely driven by the androgen hormone testosterone, one 
option is to castrate the patient -  removing the main source of testosterone production in 
the body -  and another is to treat with anti-androgens, such as bicalutamide**. More 
advanced cancers will frequently develop androgen independence in which case these 
methods are ineffective. In hormone-refractory prostate cancer, taxanes (such as 
docetaxel) may also be used**. These drugs are able to promote cell death through 
microtubule over-stabilization and/or reducing anti-apoptotic abilities of Bcl-2**. 
Bisphosponates (e.g. zoledronic acid) are used to palliatively treat patients with bone 
metastasis by reducing bone resorption**. As there is a lack of effective treatments of 
PCa in the advanced stages of disease, it is important to understand the mechanisms by 
which this disease progresses.
18
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
2 Cellular invasion in prostate cancer
Cancer cell invasion is an important event in cancer progression. Malignant tumours 
differ from their benign counterparts in that they are able to override the growth and 
localization restraints of their environment and disrupt normal tissue**. In order for this 
to occur, cells from the tumour must invade the surrounding tissue, frequently altering 
normal physiological functions for the benefit of the cancer*®. The mechanisms of 
tumour invasion are complex and different pathways of action can lead to the same 
invasive consequence. Tissue invasion requires cell adhesion, migration and proteolytic 
activity. For cells to become invasive they can mimic regular physiological functions 
that normal non-cancerous cells would not have, such as degrading the extracellular 
matrix (ECM)**. Cancer cells must also interact with their surrounding tissue, involving 
cell-cell contact, cell-ECM contact and secreted molecular factors**. Another key change 
for invasiveness is that the tumour cells must become motile, as they need to physically 
move into the surrounding tissue to invade it*®. Many of the molecular factors involved 
in invasion of prostate cancer have been elucidated.
2.1 Stromal involvement in prostate cancer invasion
Cells located in the tumour stroma can have effects on cancer invasion. Cancer- 
associated fibroblasts (CAFs) have been shown to be involved in prostate cancer**, 
especially myofibroblasts*®. CAFs can assist PCa invasion by secreting growth factors 
and in degrading the ECM through the release of extracellular proteases, and the same is 
true for cancer-associated macrophages*®. Myofibroblasts, as well as tumour cells, can 
be activated to become invasive by high levels of fibroblast growth factor-2 (FGF-2) and 
hepatocyte growth factor (HGF). Both growth factors (GFs) are found at higher levels in
19
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PCa tissue as compared to normal tissue*®. N-cadherin is also found upregulated in 
invasive PCa cells, most likely allowing for greater cell-cell interaction between cancer 
and stromal cells*®.
In PCa with very reactive stroma, the amount of interstitial collagen in the ECM 
is increased, but the collagen forms less organized structures*®. PCa tissue has also been 
found to have high levels of fibronectin, and the PCa cell line DU-145 shows an increase 
in invasiveness in an in vitro invasion assay using plasma fibronectin as a 
chemoattractant, showing a probable involvement of this protein in promoting invasion*®. 
As well, high levels of hyaluronan (HA) have been found in association with advanced 
prostate cancer**. Although PCa cells will normally adhere to HA, decreasing motility by 
maintaining cellular contact with the ECM, the hyaluronan/matrix metaloproteinase-9 
(MMP-9) receptor CD44 is found downregulated in advanced PCa cells**. It reasons that 
this aids the prostate cancer cells in motility. While HA hydrates the stroma, making for 
a motility-enhancing surface, a decrease in CD44 may mean that the cells do not strongly 
adhere to HA as they migrate**.
2.2 The basement membrane and prostate cancer cell attachment 
The normal prostate epithelial basement membrane (BM) contains many ubiquitous 
components, such as collagen IV, laminins, and proteoglycans, but also more specific 
BM molecules, such as tenascin, laminin-10 and vitronectin**. Studies have shown that 
there appears to be an increasing loss of basal lamina with higher level Gleason grade of 
the tumour**. Not only is the BM decreased in PCa, but also some components that form 
hemidesmosomes are altered upon PCa cell conversion to an invasive phenotype.
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Changes in cell-cell receptors (cadherins) as well as cell-ECM receptors 
(integrins) are prominent in the progression of PCa cells. As PCa progresses, the 
contributors to normal hemidesmosome formation, namely a6(34 integrin (laminin-5 
receptor)**, laminin-5*®’**, collagen VII**, pi integrins**, and E-cadherin*®, are all found 
at notably decreased levels. This can lead to a loss of both cell-cell interactions of the 
epithelia as well as a lower affinity to the BM, allowing cells to escape migratory 
constraints. Expression of E-cadherin is lost in the metastatic PCa cell lines LNCaP and 
PC-3*® and the a ip i  integrin (a collagen IV receptor) is lost in invasive PCa**. This 
further supports the importance of the loss of these adhesion molecules in PCa 
progression.
However, not all adhesion proteins are decreased in prostate cancer. It has been 
shown that the integrins found most often and at the highest levels in PCa are a3pi and 
a6pi, the major integrin receptors for laminin-10**. Although it could be suspected that 
this would act to hold cells more tightly to the prostate BM, these integrins may also 
allow PCa cells to adapt to new surroundings. Both the stroma of the surrounding muscle 
tissue of prostate and of bone marrow matrix (a common site for PCa metastasis) are high 
in laminin-10**, which implies that integrins a3pi and a6pi may help PCa cells survive 
in these environments.
2.3 The proteases of invasive prostate cancer
PCa cells must degrade their surrounding barriers -  especially that of the BM -  in order 
to invade adjacent tissue. Multiple protease systems have been found to be involved in 
PCa invasion.
21
R eproduced with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
2.3.1 The plasminogen activation system
The plasminogen activation system functions as a proteolytic cascade, wherein urokinase 
plasminogen activator (uPA) cleaves the zymogen plasminogen to obtain the 
enzymatically active plasmin*'*. Plasmin is a wide specificity protease that can activate 
many other proteases including MMPs, leading to a process responsible for degrading 
most components of the ECM, including those of the BM*"*. Other components of the 
plasminogen activation system include the cell surface uPA receptor (uPAR) and the two 
uPA serpin inhibitors, plasminogen activator inhibitor-1 (PAI-1) and PAI-2*'*’**.
uPA bound to uPAR is involved in PCa cell adhesion and mitogenic signals*® and 
both are often found upregulated in PCa*®. As well, the PCa cell line LNCaP has been 
shown to bind and activate latent exogenous uPA on its surface, and cell lines that 
produce their own uPA, such as DU-145 and PC3, are able to use uPA in an autocrine 
maimer*®. As the surface activity of uPA increases in these cell lines through binding the 
uPAR, so does the in vitro invasive capability to pass through a BM-like barrier*®.
2.3.2 Matrix metalloproteinases
Another family of proteases involved in PCa invasion are the matrix metalloproteinases. 
There are at least 24 Zn"̂ * dependent MMPs in humans** and in total they are capable of 
degrading nearly all known components of the ECM**. The MMPs are a family of Zn^* 
and/or Ca^*-dependent endopeptidases that are secreted as zymogens**. Their activation 
can occur via auto-proteolysis or by specific proteases such as plasmin** as well as other 
MMPs*®, a process that can progress in cascades. MMP activity is also controlled by the 
protease inhibitor a-macroglobulin (a-Mac) and tissue inhibitors of metalloproteinases 
(TIMPs)'*®. The MMP family is transcriptionally regulated by growth factors (GFs),
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hormones, and cytokines and their production is controlled by cell differentiation and 
transformation'*®. The main physiological role of MMPs is in tissue morphogenesis, 
tissue repair and angiogenesis, but they also are involved in diseases, such as rheumatoid 
arthritis, autoimmune blistering disorders of skin, and cancer**. MMPs are able to have a 
regulatory effect on the tumour’s microenvironment, and almost all invasive cancers have 
some form of upregulated MMP expression and activation'**. As well as secreted by 
cancer cells, many MMPs can be synthesized by stromal cells, and cancer cells can 
secrete factors that enhance stromal cells to transcribe and/or activate MMPs and vice 
versa**'*®. In vivo, certain MMPs are expressed at the edge of the invasive front of the 
tumours*®. However, the functions of MMPs are complex and often redundant, and so 
their role in tumour progression is not always clear; MMPs may be beneficial to cancers 
at some stages and detrimental at other times**.
The main MMPs associated with PCa are MMP-2, -7 and -9** which are secreted 
not only by tumour cells, but also by the monocytes/macrophages present in the stroma 
and stromal fibroblasts'**. Increased MMP-2**’'** and MMP-9'** protein levels are 
associated with disease progression in PCa. In breast carcinomas and melanomas, MMP- 
2 and MMP-9 activity is localized to the periphery of invading tumours at the areas of 
stromal interaction, while no activity was found in the tumour interior**. MMP-2 and 
MMP-9 are hypothesized to be required for cells to penetrate the BM, as they are 
efficient at degrading collagens IV and VII** as well as laminin and nidogen*®. In the 
interstitial ECM, MMPs are essential in degrading gelatin, the product of degraded 
fibrilar collagens**. In support of the involvement of MMPs in PCa invasion, is the 
finding that TIMP-1 levels are lower in high-grade PCa tissue samples than both normal
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tissue and more differentiated PCa'*̂ . There is also a correlation of high uPA levels with 
those of MMP-2 and MMP-9'^ .̂ In conclusion, one proposed proteolytic mechanism of 
PCa invasion via uPA is the initial cleavage of latent TGF-P and/or EOF, which in turn 
can lead to an increase in both uPA and PAI-1 followed by MMP-9 activation with 
corresponding BM degradation and cell migration'^ .̂
2.3.3 Kallikreins
Another group of proteases that normal prostate epithelial cells secrete and may 
be involved in cancer are the human kallikrein (hK) serine proteases. hKs are a family of 
15 homologous single chain serine endopeptidases, ranging in size from 25 to 30 kDa. 
They are all located on the same gene locus, and some cancers have been shown to 
aberrantly express as many as twelve of these hKs at the same time. All hKs are 
expressed in zymogen form and are activated upon cleavage and removal of their 
inhibitory pro-peptide. Various serine protease inhibitors, such as serine protease 
inhibitors (serpins) and a-Mac can inhibit their activity. Glandular epithelial cells mainly 
express these kallikreins and only a few of their physiological piuposes have been 
elucidated, such as hK3 cleaving semenogelin to increase sperm motility. In cancer, 
many hKs are improperly regulated; they are increased in some cancers, such as ovarian 
cancer while downregulated in breast and prostate cancer'̂ '̂ .
In PCa, the kallikreins hK2, hK3 (also known as PSA), hK4 and hK15, are 
present to varying degrees'^. PSA is most well known as a serum marker for prostate 
cancer. Its inhibition in the PCa cell line LNCaP using monoclonal antibodies against the 
active site"̂  ̂or Zn^  ̂as a proteolytic inhibitor'*  ̂yields decreased invasive ability through a 
simulated BM in vitro. Furthermore, PC-3 cells transfected with either PSA or hK4 show
24
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
a morphological change similar to epithelial to mesenchymal transition (EMT, as 
discussed in the following section) as shown by molecular signs of the transformation 
such as loss of E-cadherin and gain of N-cadherin'^’. However, decreases in both hK2 
and PSA levels are correlated with malignant tumours'*' ,̂ so their role is unclear.
2.4 Prostate cancer cell migration
Cell motility is needed by invading cancer cells to physically migrate through 
tissues. This can include moving from an epithelial layer through to the interstitial ECM, 
or to migrate into another tissue area. Cell migration happens through four main steps: 
protrusion, adhesion, translocation and retraction‘s*. The molecular pathways controlling 
cancer cell migration are similar to non-cancer cell migration, as regularly performed by 
immune cells and fibroblasts'**. Integrins are important in cell migration, as signalling 
pathways resulting from integrin binding can lead to increases in cellular migration'* .̂ 
Cells are able to move by reorganizing their actin cytoskeleton through polymerization, 
which helps in forming filopodia by pushing out the membrane, and -  by de­
polymerization -  releasing the cells at their trailing edge'**. The directionality of 
migration is often along gradients of certain chemical factors, such as along an ECM 
component gradient (haptotaxis) or towards soluble components (chemotaxis)^**. In 
response to this gradient, actin polymerization occurs in the area where chemo-attractant 
receptors are activated, polarizing the cells^^. Some motility-inducing factors present in
the ECM include vitronectin, frbronectin, laminin, collagens I and IV^’. Other motility 
factors include secreted factors released from stromal cells, such as histamine, insulin­
like growth factor-I (IGF-I) and interleukin-8 (IL-8), as well as cancer-cell secreted 
autocrine motility factors (AMFs), such as IGF-II and autotaxin^^. To follow these
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chemical gradients, there are three main mechanisms that cancer cells can use to migrate: 
mesenchymal, amoeboid, and collective migration. Within a given tumour, any 
combination of these three types of motilities can be present'**.
Cell migration in PCa can be activated by many soluble factors, such as AMFs, 
excess EOF receptor, as well as growth factors TGF-P, nerve growth factor (NGF), HGF 
and IGF^*. Certain integrins appear to be involved in PCa motility. The PCa cell line 
DU-H -  a DU-145 sub line selected for high a6 integrin expression -  show a greater 
degree of mobility on laminin substrates as well as elevated in vivo invasive ability 
compared to the low a6 integrin expressing sub cell line, DU-L^*. As well, levels of both 
Src kinase and focal adhesion kinase (FAK) -  proteins involved in relaying integrin 
signalling from the cell surface -  are elevated in more aggressive PCa'*̂ . Signal 
transduction activated by these proteins is correlated to an increase in PCa cell migration 
through Rac/Raf/MAPK signalling'* .̂ Expression of various ras genes -  connected to 
relaying signals from growth factor receptors -  have also been linked to advanced 
prostate cancer, and upon transfection into low-motility PCa cell lines, increase cell 
migration^*. As well, inhibitors of Ras-associated kinase (ROCK) -  a signalling protein 
associated with amoeboid motility -  are able to decrease the amount of cellular migration 
in the PC-3 cell line using an in vivo migration assay^ .̂ This is further supported by a 
decrease in myosin phosphorylation^^. Higher expression of some cell surface receptors 
results in lower PCa cell motility. Overexpression of the hyaluronan binding receptor 
CD44 correlates tvith decreased motility^*, and decreased expression of the cell-cell 
binding protein E-cadherin in rat PCa cell lines increases an invasive phenotype^*. As
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each CD44 and E-cadherin immobilize cells by attaching to their respective ligands, 
lower levels of these adhesion proteins could allow for increases in motility.
EMT may also be involved in prostate cancer invasion, as this process provides 
epithelial cells with a phenotype and mobility similar to that of mobile mesenchymal 
cells. To initiate EMT, the signalling proteins Rac and Cdc42 -  once activated by surface 
tyrosine kinases such as c-met̂ ® and various integrins^* -  begin the reorganization of the 
actin skeleton at the front of cell migration towards a chemotactic gradient'**. Cells 
employing a mesenchymal mode of motility use focal adhesion points -  with integrins as 
anchors to the ECM -  to lead the migration^^. One facet of EMT is increased expression 
of N-cadherin with decreased expression of E-cadherin induced by factors such as TGF- 
Since E-cadherin induces cell-cell interaction with neighbouring epithelial cells and 
N-cadherin induces cell-cell interaction with stromal cells, this can assist migration of 
epithelially arisen PCa by allowing cells to decrease epithelial interactions and increase 
interaction with stromal cells^^. EMT has also been induced in the PC-3 cell line by 
transfection with either PSA or hK4'*’.
2.5 Growth factor involvement in prostate cancer invasion
GFs can be in an inactive state in the ECM^  ̂ and can be secreted by either cells of the 
immune system, stroma, or the tumour cells themselves^^. GFs are important for tumour 
invasion in many ways. Once a cancer becomes invasive, signals induced by ligand- 
receptor binding can initiate pathways for cell migration, enzyme degradation, and self­
activation. Mutations in the receptors of these ligands can permanently activate positive 
signalling pathways for invasion^^. Conversely, other mutations can turn off inhibitory
27
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
signalling systems that would normally arrest cancer cell invasion^^. Two important 
growth factors involved in modulating PCa cell invasiveness are TGF-P and IGF.
2.5.1 TGF-P in prostate cancer invasion
The transforming growth factor-P family consists of TGF-pl, 2 and 3; each elicit similar 
biological effects, but differ in their tissue-specific expression pattems^^. The growth 
factors bind to TGF-P receptor I (TGF-PRI) and TGF-pRII, each of which are 
serine/threonine kinases that transmit signals into the cell mainly through the downstream 
Smad family of signalling proteins^’. TGF-p can be secreted by fibroblasts, immune 
cells, and cancer cells alike^ .̂ It can be foimd in the ECM in an inactive form associated 
with proteins in a latency-conferring complex, and becomes activated upon proteolytic 
cleavage^\
Under normal physiological circumstances, TGF-p is involved in restricting 
epithelial cell proliferation and differentiation^^, however, malignant cancer cells can 
become immune to inhibitory effects^*. In the early stages of cancer progression, TGF-P 
can inhibit cancer cell growth, induce apoptosis'*'*, and downregulate MMPs^^. However,
in later stage cancers TGF-P is often upregulated^^. Tumour promoting mutations in 
Smad proteins can lead to alterations in receptor-ligand signalling, helping cells to avoid 
suppressive effects^’. TGF-p can also assist in stimulating EMT^*, giving cells a 
migratory phenotype '̂*. This change is orchestrated through Ras and Smad signalling via 
the TGF-p receptor as well as through interactions with some integrins^*. Furthermore, 
TGF-P also has the ability to attract fibroblasts^^’”  as well as regulate autotaxin secretion 
in cancer cells^’. Additionally, it was found that latent TGF-P can be activated by MMP-
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2 and MMP-9^*. TGF-P can stimulate stromal cells to produce and secrete increased 
levels of ECM molecules, which could act as a barrier to cancer invasion” . However, 
some MMPs can cleave ECM molecules in such a way that cryptic migratory inducing 
domains are revealed, thus activating cancer cell migration instead of acting as barrier^’. 
TGF-P seems to have a pleiotropic role in cancer invasion, as it is beneficial or 
detrimental to tumour cells at different times in cancer progression^*.
In PCa invasion, TGF-P appears to play an important role. The loss of the TGF-P 
type II receptor in tumour fibroblasts -  decreasing this receptor’s regulatory effects -  as 
well as an increase in TGF-p levels in the prostate have given rise to invasiveness in 
PCa^  ̂ and correlates with a negative clinical outcome^^. PCa can become resistant to 
TGF-P inhibition while still gaining increased invasiveness^®. PCa cells are able to 
subvert the inhibitory effects of TGF-p by either altering TGF-P receptor/Smad 
expression or mutations in signalling partners, including downstream signallers^^. These 
mechanisms are also suspected of helping PCa cells to gain androgen independence^^, as 
stimulating signals from TGF-P may replace those needed for growth in PCa cells as they 
invade tissues outside of the prostate.
2.5.2 IGF in prostate cancer invasion
There are two types of insulin-like growth factors (IGF-I and IGF-II) with corresponding 
cellular receptors for each (IGF-IR and IGF-IIR), as well as six extracellular binding 
proteins (IGFBP-1 to IGFBP-6) which can bind and capture IGF-I and IGF-II 
extracellularly^®. IGF-I binding to IGF-IR on the cell surface stimulates PI3K^\ Akt 
kinase^®, and MAPK^*, promoting survival, migration and invasion̂ **. IGF-I binding to 
IGF-IR can also turn on expression of MMP-2, MMP-9 and MTI-MMP in cell lines
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developed from lung carcinoma, leading to increased invasive potential by cleaving BM 
proteins collagen IV and gelatin®®. IGFBPs, although known mostly for their role in 
sequestering IGFs, can have other modes of action. IGFBP-2, for example, has been 
linked to the progression of cancer through upregulation of invasion-related genes, such 
as MMP-2, although the mechanism by which this happens is unknown®®.
In serum of PCa patients, increased levels of IGF-I are observed®* and this GF has 
been shown to be important to PCa invasion in a number of ways. It can induce 
activation of the androgen receptor in the absence of androgens, thought to occur through 
a cross-talk between IGF-IR and androgen receptor pathways®* and may allow PCa cells 
to become androgen-independent and migrate into areas with lower androgen 
concentrations. Furthermore, IGF-IR activation leads to an increase in both MMP-2 and 
uPAR production in PCa cell lines®*. As well, the IGF-IR is found highly expressed in 
advanced prostate cancer cells®̂ . Regarding the IGF binding proteins, IGFBP-2 is 
upregulated in over 90% of prostate cancers®®, promoting an invasive phenotype through 
such means as MMP-2 upregulation. Furthermore, PSA and hK2 are each able to cleave 
IGFBP-3^, simultaneously abolishing the intrinsic anti-proliferative and apoptotic effects 
of this IGF binding protein, while at the same time freeing IGF-I®®. Finally, IGF 
produced by stromal cells can act as a chemotactic factor for PCa cells, encouraging the 
invasion of surroimding tissue^^.
3 Prostate-specific antigen
PSA was originally discovered as a forensic marker for sex crimes as it was a highly 
produced male-specific protein in seminal plasma®®. In the 1980’s, PSA was confirmed
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as a serum marker for prostate cancer®'*. Although it is a useful serum marker for prostate 
cancer, it is not very specific and its role in PCa biology and progression has not been 
fully elucidated.
3.1 Biology of PS A
PSA is a serine proteinase of the human kallikrein family, with a calculated molecular 
weight of 28.4 kDa®®. The gene encoding PSA, Mk3, is located on chromosome 19ql3.4 
next to 15 other members of the kallikrein family®®. The transcription of klk3 is 
controlled by the androgen/androgen receptor binding to androgen-responsive elements 
to activate the promoter of the gene®®. PSA is translated as 261 amino acid (aa) prepro 
zymogen with a single N-linked glycosylation on Asp-45® .̂ The 17 aa signal peptide 
(pre-domain) is cleaved off upon transport into the extracellular environment. The 
resulting pro-PSA is the latent form of the PSA enzyme, which has to be activated 
extracellularly by proteolytic cleavage of the pro domain to give the 237 aa enzymatically 
active enzyme®®.
This enzyme is true to its name, as prostate-specific antigen is expressed at levels 
in the prostate 1,000-fold that of any other bodily fluid®*. In the prostate lumen, PSA 
levels are in the 1 0 - 5 0  pM (-0.3 -  1.8 mg/ml) range where it occurs mainly in its 
enzymatically mature form®®. In seminal plasma, PSA is found at very high 
concentrations still mainly in the enzymatically active form, in concentrations ranging 
from 0.5 -  2.0 mg/ml^®. Human seminal fluid contains at least five different PSA 
isoforms, including two that are enzymatically active and three that inactive, nicked 
forms^*.
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3.2 Regulation of PSA enzymatic activity
There are four different regulatory mechanisms for proteolytic activity of PSA®®. First, 
PSA is secreted as zymogen, and needs cleavage of its N-terminal pro-region for 
activation. Once activated, binding of divalent cations to allosteric regions, internal 
proteolytic cleavage of mature PSA, or binding to protease inhibitors can all abate the 
enzymatic activity of PSA.
3.2.1 Activators of zymogen PSA
Removal of the pro-region of the PSA zymogen can be achieved through trypsin-like 
proteolytic cleavage. This enzymatic specificity is demonstrated by the fact that trypsin 
is able to activate PSA®®. Cleavage of the enzymatically inhibitory pro-peptide of PSA 
can be also accomplished by at least four other human kallikreins. The trypsin-like serine 
protease hK2 was the first protease found to cleave the pro-peptide and activate PSA®®. 
This enzyme is also able to auto-activate, and is found at an average concentration of 6.4 
mg/ml in the prostate, about 100-fold lower than that found for PSA®*. Because of these 
features, there is a strong possibility that hK2 is a physiological activator of PSA that 
leads to the liquefaction of semen. Another human kallikrein expressed almost 
exclusively in the prostate is hK4, which also displays the ability to activate latent PSA®®. 
Using recombinant hK4, strong activation of PSA was observed without any notable 
internal cleavages®"*. hK5, another trypsin-like serine protease, has been shown to auto- 
activate as well as activate both hK2 and PSA®®. Recombinant hK15 (prostin) also can 
activate PSA, and hK15 is produced primarily in the prostate®®. However, this enzyme 
needs trypsin activation before being capable of PSA activation.
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3.2.2 PSA inhibition by Zn ®
The m ain physiological inhibitor of PSA appears to be the divalent cation Zn̂ ®. It is 
thought to bind to PSA in two separate binding pockets, most likely allosterically, thus 
reducing the enzymatic activity of PSA®®. Zn®"̂  is present in the prostate at ~1 mg/g dry 
weight®*, and about 150 pg/g wet tissue, the highest concentration of any tissue known®®. 
In seminal plasma, Zn̂ ® is observed at concentrations ~2 mM"*®. PSA is inhibited by Zn̂ ® 
at concentrations as low as 10 -  100 pNT*®. The levels of Zn̂ ® in seminal fluid exceed 
that needed for PSA inhibition, suggesting possible inhibition of PSA activity while in 
the prostate.
3.2.3 Proteinase inhibitors of PSA
Various proteinase inhibitors are able to bind to active PSA and inhibit its enzymatic 
activity. These proteinase inhibitors only bind to active PSA. In the seminal plasma, 
protein C inhibitor (also known as PAI-1) is bound to 5% of active PSA where it is 
present at 3 -  4 pM*®. In the bloodstream, ai-antichymotrypsin (ACT) is a major binding 
serpin of PSA®®, where it acts by irreversibly binding to the active site of PSA through an 
acyl-bond®®. Another strong inhibitor of PSA is a-Mac, which binds and completely 
encapsulates PSA**. This binding occurs through proteolytic cleavage of the bait region 
of a-Mac by active PSA, triggering a conformational change in a-Mac to enclose PSA*®. 
Other minor proteinase inhibitors of PSA include inter-a-trypsin inhibitor, and a l -  
antitrypsin which bind to a small fraction of PSA in seminal plasma*.
3.2.4 Proteolytic inactivation of PSA
Internal cleavage of the mature region of PSA results in an irreversible inactivation of 
this enzyme. The enzymes responsible for this are suspected to be the same enzymes that
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proteolytically activate PSA. hK2 has shown the ability to cleave PSA internally -  
although at a slower rate than removal of the pro-peptide -  between Lys 145 - Lys 146, 
representing 10-25% of the PSA forms found in human seminal plasma®®. PSA is also 
internally cleaved by hK5 between Arg 86 -  Phe 86, and Lys 183 -  Ser 183®®. PSA 
isolated from human seminal plasma has been observed to be cleaved at these sites, 
suggesting that hK5 is active in seminal fluid where it is expressed along with PSA and 
hK2 and may be a physiological regulator of PSA activity®®.
3.3 Enzymatic substrates of PS A
PSA exerts its proteolytic activity using a catalytic triad characteristic of serine proteases, 
with the amino acids of the active site consisting of His-45, Asp-96 and Ser-192*®. It has 
been shown to have a weak chymotrypsin-like activity, cleaving after hydrophobic or 
basic amino acid groups*®. Semenogelins, the gel-forming proteins in semen, are thought 
to be the physiological substrate of PSA®. PSA assists in the liquefaction of semen by 
cleaving semenogelins I and 11*"* and frbronectin*®.
PSA has also been shovra to cleave proteins not involved in semen gel formation. 
PSA can cleave both IGFBP-3*® and IGFBP-4*®, releasing bound IGFs. PSA can also 
cleave the regulatory pro-peptide of latent TGF-p2 to yield a biologically active mature 
TGF-P2**’*®. As well, PSA is able to cleave and inactivate parathyroid hormone related 
protein (PTHrP), a protein involved in bone resorption and implicated in regulating 
prostate growth and calcium levels®®. Another protein hydrolysable by PSA is human 
secretory leucocyte protease inhibitor (SLPI), a protease inhibitor of granulocytic elastase 
and cathepsin G®*. SLPI is found in seminal plasma at a mean value of 22.8 mg/1 and 
functions most likely to protect sperm cells and delicate proteins during an immune
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response®*. Furthermore, PSA has been shown to cleave plasminogen to yield 
angiostatin-like fragments, peptides that are involved in angiogenesis®®. Multiple 
components of the BM have also been found to be substrates for PSA, including 
frbronectin, laminin, gelatin and fibrinogen"*®’** as well Matrigel, a simulated BM"*®.
3.4 Non-enzymatic activities o f PSA
Recently, evidence has emerged showing that PSA may have effects independent of 
proteolytic activity. By treating prostate cancer cell lines with PSA isolated from seminal 
plasma, intracellular reactive oxygen species (ROS) are produced®®. Abrogation of the 
ROS-inducing effects of PSA -  using a monoclonal antibody that did not affect the 
enzymatic activity of PSA -  shows that enzymatic activity of PSA is not necessary to 
induce ROS. Furthermore, exogenous recombinant PSA inhibits angiogenesis in vitro 
and in vivo®"*. Similar effects have been seen with enzymatically active PSA as well as an 
enzymatically inactive truncation mutant lacking the N-terminal isoleucine. The non- 
proteolytic activity of PSA may be due to ligand-receptor reactions not related to 
proteolytic activity. PSA has extensive homology with some growth factors on the amino 
acid level, notably y-nerve growth factor (56%), a-nerve growth factor (51%) and EOF 
binding protein (53%)*®’®®.
3.5 PSA testing used in prostate cancer diagnosis
The presence of PSA is measured in a patient’s serum, with levels of PSA > 10  ng/ml 
being highly predictive of PCa, levels of PSA < 4 ng/ml predicting a low percentage of 
PCa occurrence and levels of PSA between 4 and 10 ng falling in the grey zone®®. 
However, prostate cancer can even be detected in men with a serum PSA value below 4 
ng/ml®®. Other disease processes can lead to an increase in the level of PSA, such as
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BPH, urinary tract infections, and prostatitis®®. Increased serum PSA levels correlate to 
tumour volume and most probably result from leakage of PSA from the prostatic-ductal 
system -  most likely due to prostate structure damage -  into the prostatic stroma and 
subsequently into the blood stream®®.
PSA exists in several different molecular forms, and the standard serum PSA test 
measures total PSA. Total PSA consists of all immunodetectable PSA and is comprised 
of free PSA and PSA bound to the protein inhibitor ACT®®. PSA can also be present 
bound to a-Mac, which accounts for a small fraction of bound PSA®®. Because of its 
large size, a-Mac completely encapsulates PSA leaving no free epitope for detection in 
the PSA test*’®®. In serum, PSA-ACT is the predominant form (60% - 95%), whereas 5% 
- 30% of the immunodetectable PSA is free PSA®®. Free, uncomplexed PSA found in 
serum can exist in several more different forms, including two truncated forms of proPSA 
the inactive zymogen), and two minor forms of internally cleaved PSA (also called 
BPSA)®®.
To improve the use of PSA as a diagnostic tool, more specific clinical tests based 
on PSA have been developed. These include PSA density measurements, where the 
serum PSA level is divided by the prostate volume, the PSA velocity test which takes into 
accoimt the rate of increase of PSA in the serum over time, and ratios of free PSA to 
protease complexed PSA*. As well, increasing levels of serum PSA have been used to 
predict PCa relapse after radical prostatectomy, radiation therapy and hormone ablation 
therapy®®.
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3.6 The possible role of PSA in cancer invasion
PCa cells have been shown to consistently express PSA, although their levels of 
expression are lower on a per cell basis than the prostate epithelium®®. Even in androgen- 
independent PCa, PSA is more often than not expressed, most likely due to an AR 
alteration which allows activity regardless of the presence of androgens®®. Also, levels of 
Zn̂ ® -  a major inhibitor of PSA activity -  are decreased ~7 fold in PCa compared to 
normal prostatic tissue or BPH®*. Two separate research groups have shown that 
decreasing the enzymatic activity of PSA using either monoclonal antibodies against 
active PSA'*® or Zn̂ ® at enzymatically inhibitory levels "*® decreases the in vitro invasive 
potential of the PSA-producing LNCaP cells. The following sections provide possible 
mechanisms of how PSA may be involved in PCa cell invasion.
3.6.1 Degradation of ECM and BM by PSA
Degradation of components of the ECM and BM are an essential step in PCa cell 
invasion. Since PSA has shown the in vitro ability to degrade fibronectin, lam inin ,  
gelatin and fibrinogen'*®’** and Matrigel (an assemblage of many BM components)'*®, it is 
possible that some or all of these activities occur in situ. By degrading fibronectin and 
laminin, PSA is able to release integrin-mediated attachment of cells to the BM, as well 
as degrade a barrier for cells to enter into the stromal environment. In the stroma, 
degradation of gelatin (partially degraded collagens) can allow for further dissemination 
into the surrounding tissue. Furthermore, degradation of some matrix components can 
reveal cryptic sites that are used by tumour cells as a chemoattractant to induce 
migration, such as the MMP cleavage products of both laminin-5®® and laminin-10®*.
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3.6.2 Cleavage of IGFBPs by PSA
The release of IGF-I by PSA cleavage of IGFBP-3*® and IGFBP-4*® may be important in 
PCa invasion. By blocking the IGF-I receptor in PC-3 cells, both an upregulation of 
IGFBP-3 and a downregulation of MMP-2 has been found®®. Similar effects are seen in 
human androgen-independent PtdCho-3 prostate carcinoma when transfected with 
antisense cRNA to downregulate the IGF-IR®*. As well, it has been found in various PCa 
cell lines that IGF-I is able to induce uPAR expression, increasing motility and 
invasion®*. As further evidence for the role of IGF-I in PCa, increases in serum levels of 
IGF-I have been foimd increased in PCa patients*®®. This evidence suggests that IGF-I -  
normally sequestered by IGFBPs -  can increase invasive potential when released by 
PSA. The cleavage of IGFBP-3 itself also may have direct consequences for invasion 
independent of IGF-I, possibly by abolishing its intrinsic anti-proliferative and apoptotic 
effects as seen in vitro in PC-3 cells'*̂ .
3.63 Activation of latent TGF-P by PSA
TGF-P is know for is dipolar role in cancer progression. Thus, the activation of TGF- 
P by PSA may be beneficial to PCa or detrimental, depending on the cancer stage. 
Prostate epithelial cells express TGF-p2 and PSA is able to activate this GF by 
proteolytic cleavage*®. Although in early carcinogenesis this could lead to apoptosis and 
cell cycle arrest, PCa cells that have become resistant to these effects can take advantage 
of the numerous effects of TGF-P in enhancing invasion. These include EMT®"*, 
activating tumour fibroblasts®®, and subverting androgen-suppressing effects through 
signalling pathway crosstalk®®.
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4 Objectives
The purpose of this study was to fiirther test the ability of PSA to change the in vitro 
invasive ability of PCa cell lines. The ability of PSA to affect invasion of PCa cell lines 
needs to be further studied. Others have shown that the invasion of LNCaP cells is 
decreased when the enzymatic activity of PSA is abolished*® '*®, however, PC-3 cells 
transfected with PSA show an increase in migration, but not invasion'*®. To test the 
migration of cells, transwell membranes were used where the number of cells crossing a 
porous membrane represented cell migration. To test for cellular invasion, these 
transwell membranes were coated with a basement membrane extract (BME) to simulate 
a basement membrane as a barrier for cellular invasion. Two different methods were 
used to test the effect of PSA on invasion. Firstly, exogenous PSA -  isolated from 
human seminal plasma -  was added to PCa cells in invasion/migration chambers to test 
the effects of this enzyme on invasion and migration. Both the PSA-producing PCa cell 
line LNCaP and the non-PSA producing PCa cell line DU-145 were used. Secondly, we 
created separate expression vectors that encoded for preproPSA as well as a deletion 
mutant prePSA that consisted of an in-frame fusion between the pre secretory region and 
mature PSA. Two vector systems were used: one system controlled PSA under the high 
expression level CMV promoter, and the other controlled PSA expression using an 
ecdysone-inducible transcription initiator. These constructs were used to transfect DU- 
145 cells to allow for either preproPSA or prePSA expression. The effects of stable PSA 
expression in DU-145 clones were examined with regards to cell growth, invasion and 
migration.
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5 Hypothesis
Exogenous PSA added to prostate cancer cells or prostate cancer cells that are genetically 
modified to secrete different forms of PSA will have a different invasive potential 
compared to cells that secrete mainly proPSA or no PSA at all.
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Materials and Methods
Cell culture
DU-145 and LNCaP human prostate cancer cell lines were obtained from ATCC. DU- 
145 cells were maintained in MEM with Earle’s salts (Sigma) -  supplemented with 1 mM 
sodium pyruvate (HyClone), 0.1 mM MEM non-essential amino acids (HyClone), 
antibiotics (100 units/ml penicillin sodium, 100 pg/ml streptomycin sulphate and 0.25 
pg/ml amphotericin B, obtained from Invitrogen), and 10% characterized FBS 
(HyClone). The LNCaP cell line was maintained in RPMl 1640 (Sigma) supplemented 
with 10 mM HEPES, antibiotics (100 units/ml penicillin sodium, 100 pg/ml streptomycin 
sulphate and 0.25 pg/ml amphotericin B, obtained from Invitrogen) and 10% 
characterized FBS (HyClone). The medium was changed three to four times per week 
and cells were passaged once or twice per week using 0.05% trypsin/5 mM EDTA 
(Invitrogen). Cell numbers and viability were determined using a Neubauer improved 
haemocytometer (La Fontaine) and 0.08% trypan blue (Gibco). Cells were alternatively 
counted using a Z1 Series Coulter Coimter (Beckman). Cells were frozen at a 
concentration of 1 -  4 X 10® cells/ml in a mixture of 50% FBS (HyClone), 43% growth 
medium, and 7% DMSO (Sigma) in Cryogenic vials (Nalgene) at -80 °C overnight and 
transferred to liquid nitrogen the next day.
Standard molecular biology methods 
Polymerase chain reaction (PCR)
PCR primers were designed using Gene Runner version 3.05 for Windows (Hastings 
Software) and were purchased from Invitrogen. All PCR reactions were run with a Deep
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Vent Polymerase Kit (NEB Labs) or an Accutaq LA DNA polymerase kit (Sigma) using 
a Genius Thermal Cycler (Techne) and the conditions shown in Table 1 unless otherwise 
indicated. In a 50 pi volume, each PCR reaction mixture consisted of 0.2 pM of each 
forward and reverse primer, 0.5 mM dNTPs, 1 X PCR mix, and 2.5 U DNA polymerase. 
A list of all primers used is shown in Table 2. The PCR products were verified by 
electrophoresis in 1% agarose gel polymerized with 1 pg/ml ethidium bromide in 1 X 
TBE at 80 V for 30 minutes to 1 hour and visualized via DNA-bound ethidium bromide- 
induced UV fluorescence. DNA molecular weight markers used in gel electrophoresis at 
10 pl/lane were obtained from Fermentas. DNA was isolated from gel excisions using a 
QIAquick gel extraction kit (Qiagen). DNA concentrations were measured by a 
BioPhotometer (Eppendorf) using Uvettes (Eppendorf) at 260 nm.
Table 1: Conditions for PCR amplification reactions
Cycle Temperature (°C) Time Number of Cycles
Initial Dénaturation 95 30 sec 1
Denaturing 95 30 sec
35Annealing variable 30 sec
Extension 72 1 min
Final Extension 72 10 min 1
Table 2: Primers used in PCR amplification reactions
Primer Name Primer Sequence (5’ -  3’)
sense pcDNAS.PSA prepro primer A+C GTTGAGCTAGCACCATGTGGGTCCCGGTTGT
as new A pcDNA3.PSA prepro primer CATCACCTGGCCTGAGGAATC
sense b modpSTHMppPSA GGCGTGGATAGCGGTTTGAC
anti-sense b modpSTHMppPSA CGGAGCAGCATGAGGTCGTG
s mid modpSTHMppPSA CCGTGACGTGGATTGGTGCTATTGTGGGAGGCTGGGAGTG
as mid modpSTHMppPSA CACTCCCAGCCTCCCACAATAGCACCAATCCACGTCACGG
s BamHI pmodSTHM to pEGSH GTTGAGGATCCGCCACCATGTGGGTCCCGGTTG
as BamHI pmodSTHM to pEGSH GATGGTCGACGGCGCTATTCAG
PSA sense B 225-246 GGTCGGCACAGCCTGTTTCATC
PSA anti-sense B 582-603 GCGTCCAGCACACAGCATGAAC
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Restriction enzyme digestion
Restriction digests were performed using enzymes acquired from Fermentas and using 
conditions and buffers as recommended by the manufacturer. In a 20 pi reaction mix, ~5 
units of restriction enzyme were used to cleave 0.2 pg -  2 pg DNA overnight at 37 °C. 
The restriction enzymes were inactivated by heating at 65 °C or 80 °C (depending on the 
specific enzyme) for 10 minutes. Restriction digest products were run on a 1% 
agarose/TBE gel, gel-excised and purified using QIAquick gel extraction kit (Qiagen). 
Linearized plasmids were purified directly using the “DNA cleanup from enzymatic 
reactions” method in the QIAquick gel extraction kit. Extracted DNA was collected in 
ddH20 or TE buffer (10 mM Tris-HCl pH 7.5,1 mM EDTA).
DNA ligation reaction, transformation of bacteria, and DNA mini-prep 
DNA ligations were performed using an overnight ligation in a low melting point agarose 
gel mixture. After restriction digestion of ~2 pg plasmid DNA and -0.2 -  0.6 pg PCR 
product, digestion products were run on a 1.2 -  1.5% low melting point agarose gel in 1 
X TBE with 1 pg/ml ethidium bromide. Appropriate restriction fragments were gel- 
excised and each excision fragment melted at 65 °C. For ligation reactions, melted gel 
fragments containing 0.01 pg -  0.1 pg digested plasmid (in -2  pi) and 0.01 pg -  0.1 pg 
restriction enzyme digest PCR amplicons (in -10 pi) were combined. Both were added 
to a mixture of 1 X T4 DNA ligase buffer and T4 DNA ligase (2U) (Promega) in a total 
of 40 pi and left at room temperature overnight. The next day, the ligation mixture was 
melted at 65 °C and added to 80 pi cold TCM buffer (10 mM Tris-HCl pH 7.5, 10 mM 
CaCL, 10 mM MgCL). 20 pi of this TCM/ligation mixture was added to 40 pi of 
competent JM109 Kcoli (Promega) at >10® cfii/pg and put on ice for 10 minutes. To
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transform bacteria, the bacteria were heat-shocked for 45 seconds at 42 °C, then put on 
ice for 2 minutes. 400 pi S.O.C. medium was added to the bacteria and the mixture 
incubated at 37 °C for one hour at 225 RPM. Dependent on the resistance encoded by the 
plasmid, 100 -  200 pi bacteria were grown on selective agar plates containing either 50 
pg/ml ampicillin or 50 pg/ml kanomycin overnight at 37 °C. Single colonies were 
isolated and grown in selective 5 ml LB media at 37 °C for one day at 225 RPM. Plasmid 
DNA from each culture was isolated using QIAprep spin miniprep kits (Qiagen) and 
tested for the correct DNA insert using restriction enzyme digestions.
Large scale isolation of plasmid DNA
To isolate large amounts of plasmids, 100 pi to 1 ml bacteria containing the correct 
plasmids (as determined by Miniprep and subsequent restriction enzyme digest) were 
grown in selective LB media specific for each plasmid (50 pg/ml ampicillin or 50 pg/ml 
kanomycin). The bacteria transformed with plasmid DNA were isolated by either midi- 
preps using a Flexiprep kit (Amersham) from a culture of 25 -  100 ml or by maxi-preps 
using QIAfilter plasmid maxi kit (Qiagen) from a culture of 100 -  400 ml grown 
overnight at 37 °C with 225 RPM shaking. Plasmid DNA isolated from the midi-preps or 
maxi-preps was further purified by ethanol precipitation using 1/10 of a volume of 3M 
sodium acetate and 2 times volume of ice-cold 100% ethanol and precipitated at -80 °C. 
DNA was redissolved in ddH20. To verify inserts, plasmids were sequenced at Paleo 
DNA Laboratories using specific primers for each plasmid.
Isolation of genomic DNA from mammalian cell lines
Cells were either trypsinized from a 10 cm cell culture plate or thawed from frozen 
cryogenic vials and centrifuged at 250 g for 5 minutes. Cells were washed with PBS and
44
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
again centrifuged at 250 g. Genomic DNA was isolated using an Ultra Clean Tissue 
DNA Isolation Kit (Mo Bio) as per the manufacturer’s instructions, and eluted in 50 pi 
TE buffer.
Vector systems used 
modpSecT agPS A
The modpSecTagPSA plasmid contains a CMV promoter for high-level expression of 
cloned genes and is the template for all CMV plasmid systems used. This plasmid was 
created from a modified plasmid by ligating the 478 bp Clal and Xbal restriction 
fragments from pcDNAS.PSA -  a plasmid containing full length PSA cDNA (a kind gift 
from Dr. Hans Krause, Free University, Berlin) -  into the 6.0 kb Clal and Xbal restriction 
fragment from pSecTag2/Hygro/PSA (Invitrogen). The resulting plasmid 
modpSecTagPSA contains a 3’ stop codon at the end of the PSA cDNA coding sequence 
before the His or Myc tags located on the pSecTag2/Hygro/PSA. The 5’ end of the 
newly created modpSecTagPSA contained a truncated PSA sequence lacking the prepro 
sequence with a leading murine IgK-chain V-J2-C signal peptide for secretion. 
Ponasterone-inducible complete control® system
The Complete control® mammalian expression system (Stratagene) consists of a system 
of 2 plasmids for dual transfection into mammalian cells: pERV3 and pEGSH. The 
pERV3 plasmid contains the VgEcR gene, a transcriptional regulator that activates 
transcription in the presence of ponasterone A (PonA, Invitrogen) -  an analogue of the 
insect hormone ecdysone -  and represses basal transcription in the absence of PonA. 
This transcriptional regulation occurs at E/GRE recognition sequences, which are present 
in the pEGSH plasmid. The pEGSH plasmid also contains a multiple cloning site (MCS)
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downstream of the E/GRE sequences to allow inducible expression of the inserted gene. 
Using this system, DU-145 cells were first stably transfected with the pERV3. Several 
clones were selected using transient transfection with pEGSH-luc -  a plasmid with the 
luciferase gene in the MCS of pEGSH -  into clones stably expressing VgEcR, showing 
inducible expression of the luciferase gene by PonA. The pERV3 containing clone with 
the largest inducible expression and the least expression without PonA was subsequently 
transfected with a pEGSH plasmid containing the gene of interest.
Transient transfection of DU-145 cells
Transient expression of PSA was done using lipofection of DU-145 cells with plasmid 
DNA containing the DNA sequence coding for PSA. DU-145 cells were seeded at 5 X 
10* cells/well in a 24-well plate (Coming) in 400 pi antibiotic-ffee media and allowed to 
adhere overnight. The next day, 50 pi Opti-MEM (Gibco) was mixed with 0.5 pg or 1.0 
pg plasmid DNA, and in a separate tube 50 pi Opti-MEM (Gibco) was mixed with 6 pg 
(3 pi) Lipofectamine (Invitrogen). The contents of the two tubes were mixed and left at 
room temperature for 20 minutes. During this time, media was removed from the cells in 
the 24-well plates and replaced with 200 pi of Opti-MEM. After 20 minutes, the Opti- 
MEM was removed from the cells and 100 pi of the plasmid/lipofectamine mixture was 
added to the cells for -20 hours. After this time, the lipofection/DNA mixture was 
removed and 400 pi DU-145 media was added. 100 pi conditioned media (CM) was 
removed after two days and then again after four days. Samples were subjected to 
Western blot analysis to determine the expression of PSA, as described in the “Western 
blot analysis” section.
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Stable transfection of DU-145 cells using electroporation 
Standard stable clone creation using electroporation
To prepare DU-145 cells for electroporation, the cells were trypsinized, centrifuged at 
200 g for 5 minutes, and resuspended in ice-cold PBS at 1 X 10® cells/ml. Gene Puiser 
Cuvettes (Biorad) were filled with 400 pi cell suspension (4 X 10® cells) and between 1 
pg to 10 pg plasmid DNA in ddHzO. For some transfections, plasmid DNA was 
linearized by digesting with a restriction enzyme overnight before transfection, and the 
DNA purified using a QIAquick gel extraction kit (Qiagen) enzyme cleanup procedure. 
The cuvettes were put in a Gene Puiser II (Biorad) and subjected to voltages between 
1000 V and 1500 V with either 1 or 2 pulses at 25 pF unless otherwise stated. Cells were 
resuspended in DU-145 growth media and seeded in 10-cm cell culture plates (Coming). 
Stable clone selection
Twenty-four hours after electroporation, the medium was replaced with growth medium 
supplemented with selective agents appropriate for the transfected plasmid (G418 or 
Hygromycin, Invitrogen) at a concentration that leads to >95% cell death, as determined 
in “Cvtotoxicitv of antibiotics used in stable clone selection”. The selective medium was 
replaced three times per week to remove unsuccessfully transfected cells killed by the 
selective agents. Once large single colonies were visible on the plate (~1 mm to 5 mm), 
they were isolated using cloning rings via trypsinization and grown in 6-well culture 
dishes. Once cells reached -70% confluency, they were transferred to 10-cm cell culture 
plates. Upon reaching -70% confluency in the 10 cm plates, a fraction of the cells in the 
plate were frozen in liquid nitrogen and the rest of the cells passaged for further study.
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Luciferase assay for detection o f a stable DU-pERV3 clone 
A luciferase assay was used to determine the active presence of the ponasterone regulated 
transcription factor VgEcR of the pERVB plasmid in transfected DU-145 cells. A 
modified version of the “Active Lysis Protocol...” from the Luciferase Assay Kit 
(Stratagene) was performed. Initially, DU-pERV3 clones were seeded at 3 X 10® 
cells/well in a 6-well plate with 2 ml of antibiotic-free DU-145 media and allowed to 
adhere overnight. The next day, 250 pi Opti-MEM (Gibco) was mixed with 0.1 pg to 7.5 
pg of pEGSH-Luc plasmid DNA, and in a separate tube 250 pi Opti-MEM (Gibco) was 
mixed with 30 pg (15 pi) Lipofectamine (Invitrogen). The two tubes were mixed and left 
at room temperature for 20 minutes. During this time, media was removed from the cells 
in the 6-well plates and replaced with 2 ml of Opti-MEM. After 20 minutes, the Opti- 
MEM was removed from the cells and 500 pi of the plasmid/lipofectamine mixture was 
added to the cells for -20 hours. After this time, the lipofection/DNA mixture was 
removed and each well was washed with PBS, and 2 ml antibiotic-free DU-145 media 
was added. To each well, various amounts of PonA -  from 0 pM to 10 pM -  were added 
24 hours later, the medium was removed and the cells washed twice with PBS. To the 
washed cells was added from 75 pi -  100 pi cell lysis buffer (25 mM Tris-phosphate pH 
7.8, 2 mM DTT, 2 mM l,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% 
glycerol, and 1% Triton® X-100) and the cell/lysate buffer mixture was scraped into a 
microcentrifuge tube. The mixture was frozen at -80 °C for 20 minutes and then thawed 
briefly at 37 °C and vortexed for 20 seconds. 50 pi - 75 pi cell lysate (CL) was added to 
100 pi luciferase substrate-assay buffer and after waiting -8  seconds, the luminescence
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was measured over 30 seconds on a Fluorostar Optima (BMG Labs) plate reader. 
Relative luminescence units (RLU) were recorded as a measure of luciferase activity. 
Western blot analysis for PSA detection
Cell conditioned media and/or cell lysates were collected from cells growing for 3-6 days 
and frozen at -20 °C in 6 X non-reducing sample buffer (350 mM Tris-HCl pH 6.8, 30% 
glycerol, 10% SDS, and 0.12% bromophenol blue). To prepare conditioned media, cells 
were grown to 50 -  90% confluency. Serum-containing media were removed, cells were 
washed with PBS and serum-free (SF) media was added to the cells. The cells were kept 
in the SF media for 3 -  6 days until the media was collected. For conditioned medium 
(CM) concentration, the collected CM was centrifuged for 10 minutes at 3,000 g to 
remove cells and large debris. The supernatant (CM) was added to 10 kDa cut-off YM- 
10 Centricon Centrifugal Filter Units (Millipore) and centrifuged at 4,000 g for 30 min -  
4 hours. Concentrated CM was collected and the fold concentration was determined by 
the difference in fluid weight before and after centrifugation. To prepare cell lysates, 
cells were trypsinized and then centrifuged at 250 g for 5 minutes. Cells were washed 
with PBS, and then centrifuged again at 250 g. The pellet was resuspended in 100 pi NB 
buffer with PMSF (0.25M Sucrose, 0.2M NaCl, lOmM Tris-HCl pH 8.0, 2mM MgCli, 
ImM CaClz, 1% TritonX-100, and ImM PMSF) to lyse cells for 5 minutes on ice. The 
lysed cells were then centrifuged at 14,000 g in a microcentrifiige for 30 seconds. The 
supernatant was removed from the pellet of cell debris into a separate tube. For CL 
isolated from cells in 6-well and 24-well plates, 75 pi of the supernatant was removed 
from the solution and frozen at -20 °C with 15 pi of 6 X non-reducing sample buffer 
(total volume of 90 pi). For CL isolated from cells grown in 10 cm or larger plates, 150
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pi NB buffer with PMSF was added as a diluent to 75 pi of the CL and the samples 
frozen at -20 °C with 45 pi of 6 X non-reducing sample buffer (total volume of 270 pi). 
As a positive control for the blots, commercially available PSA isolated from seminal 
plasma was used (Human prostate-specific antigen purified protein (AG650, Chemicon) 
or Prostate-Specific Antigen enzymatically active (ActPSA, Fitzgerald)). As a molecular 
weight marker, 10 pi to 15 pi Prestained SDS-PAGE standards (Bio-Rad) were loaded in 
at least one well of each gel. Proteins in the samples were separated on a 12% poly­
acrylamide 0.1% SDS gel with a 4% stacking gel and a running buffer of 190 mM 
glycine, 25 mM Tris base, and 0.05% SDS at 100 V. The proteins were transferred to 
Hybond nitrocellulose (Amersham) in a carbonate transfer buffer (17 mM NaHCOs, 5 
mM NazCOs with 20% methanol) overnight at 20 V. The nitrocellulose blot was 
equilibrated for 10 minutes in TBST, and subsequently non-specific sites were blocked 
for 1 hour in TBST containing 8% powdered skim milk. The blot was transferred to a 
solution of mouse anti-PSA antibody A67-B/E3 (Santa Cruz) at 1:400 (0.5 pg/ml) in 
TBST with 5% powdered skim milk for 1.5 hours. After four 15-minute washes with 
TBST, the blot was incubated in a solution of goat anti-mouse IgG horseradish 
peroxidase-conjugated antibody (Santa Cruz) at a 1:2000 dilution (0.2 pg/ml) with 5% 
powdered milk in TBST. The blot was washed four times for 15 minutes in TBST. 
Detection of HRP was carried out using an enhanced chemiluminescence method as 
follows: the blot was transferred to a solution of 100 mM Tris-HCl pH 8.5, 9 X 10'  ̂% 
H2O2 , 200 pM coumeric acid (Sigma) and 1.25 mM luminol (Sigma) for 1 minute. The 
blot was removed from the solution and exposed to Scientific imaging X-ray film 
(Kodak) for protein band detection. Densitometry of the bands was carried out using
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Kodak ID version 3.5 imaging software, and PSA concentrations were calculated using a 
standard curve determined by running three concentrations of ActPSA (1-20 ng/lane) on 
a Western blot.
Cell number determination using relative DNA content 
Standard curve to determine cell numbers
To create standard curves, DU-145 cells were serially diluted from 6.0 X lO"' to 4.7 X 10  ̂
cells in serum-supplemented medium, halving the cell number with each dilution. 
LNCaP cells were similarly serially diluted from 3.2 X 10"* to 1.0 X 10̂  cells. Cells were 
seeded in four replicates of 200 pi medium/well in a 96-well plate and allowed to adhere 
overnight. The next day, media was removed from each well of the plate, replaced with 
100 pi of ddHzO, and frozen at -80 °C to lyse the cells and determine the DNA content as 
described in section “Measuring DNA to determine relative cell number”. The DNA 
content determined in relative fluorescence units (RFU) was correlated with cell number 
to obtain a linear correlation between RFU and cell number.
Growth curve analysis
For growth assays, cells were plated at 1.0 X 10̂  (DU-145) or 5.0 X 10̂  (LNCaP) cells 
per well in clear 96-well cell culture plates (Coming) with 200 pi media specific to each 
cell type and experiment. In total, five identical plates were seeded, to be removed one 
per day. Cells were allowed to adhere overnight. In experiments using PonA, cells were 
plated in serum-containing media with 1 pM or 10 pM PonA along with the 100% 
ethanol (solvent) controls. In experiments using exogenous PSA, media was removed 
after the cells were allowed to adhere overnight and was replaced with serum- 
supplemented media containing 0.5 pg/ml, 1 pg/ml or 2 pg/ml PSA (AG650 or ActPSA),
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with the appropriate PBS buffer controls. Each day, over a period of 5 days, media was 
removed from each well of one plate, replaced with 100 pi of ddHzO, and frozen at -80 
°C to lyse the cells and determine the DNA content as described in section “Measuring 
DNA to determine relative cell number”. A logarithmic growth curve was created from 
this data, and using the slope of the growth curve from days 3 -  5 the population- 
doubling time (PDT) was determined using Excel (Microsoft).
Cytotoxicity of antibiotics used in stable clone selection
To determine the concentration of antibiotic needed to decrease cell numbers by 95%, 
DU-145 cells (or selected transfected DU-145 subclones) were plated at 400 cells/well in 
100 pi growth medium and allowed to adhere overnight. The next day, either (or both) of 
the antibiotics hygromycin B (Invitrogen) and G418 (Invitrogen) at concentrations 
ranging from 50 pg/ml to 900 pg/ml were added to the cells in 100 pi growth medium. 
Five days after the antibiotics were added to the wells, media was removed from each 
well, replaced with 100 pi of ddH20, and frozen at -80 °C to lyse the cells and determine 
the DNA content as described in the next section.
Measuring DNA to determine relative cell number using Hoechst 33258
Frozen plates containing the lysed cells were placed at room temperature to thaw. To 
each well containing the lysed cells in 100 pi ddH2 0 , a 100 pi solution of 20 pg/ml 
Hoechst 33258 (Sigma) in TNE buffer (10 mM Tris-HCl pH 7.4, 2 M NaCl, 1 mM 
EDTA) was added and placed in the dark for 5 minutes. Hoechst 33258 binds to DNA 
from the lysed cells, resulting in a fluorescence shift to 460 nm, and a linear relationship 
between DNA and cell number is seen over a wide range of DNA. The DNA amount is 
directly proportional to cell number. The DNA-Hoechst fluorescence was measured
52
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
using an excitation of 360 nm and emission of 460 nm on a FLxSOO Multi-Detection 
Microplate Reader (Bio-Tek).
Activity assay to test for enzymatically active PSA
Enzymatic activity of PSA was measured using the cleavage of /?-nitro-analine from the 
peptide substrate MeO-Suc-Arg-Pro-Tyr-pNA (S-2586, Chromogenix) in a 96-well plate. 
Each 240 pi reaction mix (per well) consisted of 200 pi activity buffer (200 mM Tris- 
HCl pH 8.0, 5 mM EDTA), 20 pi of either 5 mM or 10 mM S-2586, and 20 pi sample. 
This gave final concentrations of 167 mM Tris-HCl, 4 mM EDTA, and either 0.4 mM or 
0.8 mM S-2586. The enzymatic activity was measured with or without 100 pg/ml of the 
irreversible chymotrypsin inhibitor TPCK (Sigma). Solutions were pipetted in a 96-well 
clear cell culture plate (Falcon) and incubated at 37 °C. Absorbance readings were taken 
hourly at 405 nm on a Powerwave XS microplate spectrophotometer (Biotek). Increasing 
absorbance at 405 nm corresponded to the release of p-nitro-analine from S-2586 due to 
enzymatic activity and results were calculated as AA405/hour.
Cell invasion/migration assay
Standard curve to determine cell numbers using calcein AM
Cell number was correlated with calcein AM RFU to create a standard curve using the 
method as stated in the “96 Well BME Cell Invasion Assay” (Trevigen). To create a 
standard curve, cells were serially diluted and plated from 5.0 X 10"* to 1.0 X 10'* 
cells/well in 50 pi of proprietary “cell dissociation solution” (Trevigen) in an opaque 96- 
well plate. To this was added 50 pi of “cell dissociation solution” with 4 pg/ml calcein 
AM, for a final concentration of 2 pg/ml calcein AM/well. This cell solution was 
incubated for one hour at 37 °C and 5% CO2 . Viable cells take up calcein AM, which
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inside the cell, is then converted to the fluorescent calcein, accumulating inside the cell. 
The resulting fluorescence of the calcein within the cells was measured using an 
excitation of 485 nm and an emission of 520 nm using the top reader of a FLx800 Multi- 
Detection Microplate Reader (Bio-Tek).
Measuring cell invasion/migration
To determine the in vitro invasive or migratory ability of prostate cancer cell lines, “96 
Well BME Cell Invasion Assay” (Trevigen) kits were used. 10-cm culture plates with 
cells at 50 -  90% confluency were washed three times with 5 ml of PBS and SF media 
was added overnight. For invasion assays, BME was plated on the membrane of the 
transmembrane chamber at concentrations ranging from 0.1 -  0.05 mg/well for DU-145 
cells (as well as subclones made from this cell line) and 0.05 to 0.01 mg/well for LNCaP 
cells. To test cell migration, no BME was added. The following day, the SF medium 
was removed from the 10 cm plates and the cells were trypsinized, resuspended in SF 
medium, and centrifuged at 250 g for 5 minutes. Supernatant was carefiilly removed and 
the cells were resuspended in SF medium. To each insert was added 50 pi cells with 
either 1.0 X 10̂  or 5.0 X 1 O'* cells/insert for LNCaP cells and 5.0 X lO'* cells/insert for 
DU-145 cells. To the lower chamber of the transwell was added 150 pi of either 0.5 or 
10% FBS growth medium as a chemoattractant. Invasion plates were incubated for 24 
hours at 37 °C and 5% CO2. The next day, the top chamber was washed once with PBS 
and the bottom chamber washed two times with PBS. The invaded/migrated cells were 
dissociated from the bottom of the insert by adding 100 pi of proprietary “cell 
dissociation solution” (Trevigen) containing 2 pg/ml calcein AM in the bottom well 
(while the insert sits in it) and incubating the plate 1 hour at 37 °C with 5% CO2 . The
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resulting fluorescence of calcein within the cells was measured by an excitation of 485 
nm and an emission of 520 nm using the top reader of an FL X 800 Multi-detection 
microplate reader (Bio-Tek). Cell number was determined using calculations from cell 
type specific calcein AM standard cell curves as described previously.
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Results
Western blot analysis of different PSA sources
To determine the expression of PSA by the human prostate cancer cell lines LNCaP and 
DU-145, Western blot analysis, using CM and CL, were carried out. These results were 
compared to commercially available PSA from different sources. AG650 and ActPSA 
are each isolated from human seminal plasma. AG650 PSA presented as a major band at 
29 kDa by Western blot analysis (Figure lA). This band most likely corresponds to 
mature PSA. When overexposed, additional bands were detected: one minor band visible 
slightly above (32 kDa) and one slightly below (26 kDa) the major band as well as a band 
at 56 kDa and another band above the 107 kDa molecular marker (Figure IB). The bands 
at 26 kDa and 32 kDa most likely represent different molecular forms of PSA (i.e. either 
an internally cleaved form of PSA and zymogen form of PSA, respectively, or PSA with 
altered glycosylation patterns), and the band above 107 kDa may represent a complex 
formed between PSA and a protease inhibitor. Although the band at 56 kDa does not 
correspond to any known form of PSA, this may be due to protein dimerization in the 
stacking gel from excess ammonium persulphate.
Western blotting of ActPSA presented two separate bands: an upper band at 33 
kDa and a lower band at 29 kDa (Figure lA). This stands in contrast to the company’s 
claim that ActPSA runs as a single band on SDS-PAGE. It is possible that these two 
forms both represent active PSA, yet differ in glycosylation patterns or some other post- 
translational modification and so run aberrantly in SDS-PAGE****. It is also possible that 
the 33 kDa band represents proPSA. Further bands were not detected, even upon 
overexposure.
56
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Western blot analysis of conditioned media obtained from the androgen-sensitive 
LNCaP cells showed a single band at 29 kDa (Figure ICL Both conditioned media and 
cell lysates obtained from the androgen-insensitive DU-145 cells were negative for PSA 
(Figure 1C), even when DU-145 CM was concentrated 26 times using a 10 kDa 
Centricon filtration unit (Figure ID). Thus, LNCaP cells produced PSA, while DU-145 




Figure 1: Western blotting for PSA of samples of cell-conditioned media and commercially isolated
PSA
Western blotting for PSA of samples obtained from various sources. A) AG650: 20 ng; ActPSA: 20 ng. B) 
AG650: 20 ng. C) LNCaP CM: 30 pi from 6 ml media conditioned 5 days by 2 X 10* LNCaP cells. D) DU- 
145 CM: 10 pi from 6 ml media conditioned 3 days by 2 X 10* DU-145 cells; DU-145 CL: 41 pg cell 
lysate from the same DU-145 cells. E) ActPSA: 20 ng; DU-145 CM conc. 26X: 100 pi from 6 ml media 
conditioned 3 days by ~ 2 X 10* DU-145 cells. (Molecular weight markers in kDa).
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Standard curves to relate cell number to DNA-Hoechst 33258 fluorescence 
In order to directly associate cell number to Hoechst-DNA fluorescence, standard cell 
curves were created for each DU-145 and LNCaP cell lines. Cells were serially diluted 
and allowed to adhere overnight in order to find the linear range correlating cell number 
to fluorescence (RFU). The standard curves created using DU-145 and LNCaP cells are 
shown in Figure 2. For DU-145 cells, the linear range was found to be 4.7 X 10  ̂-  6.0 X 
ID'* cells/well and, using a standard curve created fi'om a linear regression function, 0.461 
RFU was found to represent one cell (R  ̂of 0.9877). For LNCaP cells, the linear range 
was found to be 1 X 10̂  -  3 X 10“* cells/well and, using a standard curve created fi'om a 
linear regression function, 0.425 RFU was found to represent one cell (R  ̂ of 0.9841). 
These values were used to determine cell number fiom RFU in future experiments using 
the Hoechst assay.
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Figure 2: Standard curves relating cell number to DNA-Hoechst fluorescence
DU-145 and LNCaP cells were serially diluted, seeded in 96-well plates and allowed to adhere overnight. 
To relate cell numbers to Hoechst-DNA fluorescence, standard curve plates were subjected to the Hoechst- 
DNA fluorescence assay. Linear regression was used to create a standard curve relating RFU and cell 
number. DU-145 cells yielded 0.461 RFU/cell (R  ̂= 0.9877) while LNCaP cells gave 0.425 RFU/cell (R  ̂
= 0.9841). Error bars represent standard deviation from 4 duplicates.
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Enzymatic activity of PSA on the synthetic peptide substrate S-2586 
In order to test the enzymatic activity of PSA, proteolytic cleavage of the chromogenic 
substrate S-2586 was used as an indicator for the enzyme’s chymotrypsin-like activity. 
This synthetic peptide contains para-nitro analine on the C-terminus and, upon enzymatic 
release from the peptide, absorbs light at 405 nm. The change in absorbance at 405 nm 
over time is therefore an indicator of specific enzymatic activity for chymotrypsin-like 
enzymes, including PSA. S-2586 is not activated by other kallikreins with trypsin-like 
activity, such as hK2^ .̂ Both AG650 and ActPSA showed similarly low activity towards 
this substrate (Table 3). TPCK -  an irreversible proteinase inhibitor of chymotrypsin -  
was added to determine if there was an inhibitory effect on the enzymatic activity of 
AG650 in PBS. As shown in Table 3, TPCK did not change the enzymatic activity.
Table 3: Enzymatic Activity of PSA on S-2586
PSA Source* Activity (AAtos/hour/pgPSA/ml)
Control 100 pg/ml TPCK
AG650 0.0028 ±0.0013 0.0028 ± 0.0002
ActPSA 0.0032 ± 0.0010 -
Enzymatic activity of PSA on the peptide substrate S-2586 was followed hourly over six hours to 
determine AAtos/hour/pgPSA/ml. Error is represented at ± standard deviation in duplicate reactions 
within 1-2 separate experiments.
Effect of exogenous PSA on cell growth
Since it has been shown that PSA has an effect on cell proliferation in osteoblasts*®, as 
well as prostate stromal cells*®̂ , the effect of exogenous PSA on the proliferation of the 
prostate cancer cell lines DU-145 and LNCaP was investigated. Knowledge of any 
changes in cell proliferation due to PSA was also important in order to account for 
variation in cell number in future migration/invasion experiments. Cells were seeded and
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allowed to adhere overnight and the next day, AG650 PSA and ActPSA were added to 
cells at concentrations of 0.5, 1 and 2 pg/ml in five separate cell culture plates along with 
controls. At 0, 24, 48, 72 and 96 hours, cell numbers were determined for each PSA 
concentration using Hoechst-DNA standard curves relating RFU to cell number. Using 
these data, the PDFs were calculated over the logarithmic growth time period from 48 to 
96 hours.
The PDT of DU-145 cells amounted to 23.1 ± 1.3 hours /Figure 3A.RL whereas 
the LNCaP cells grew more slowly, with a PDT of 31.0 ± 5.0 hours (Figure 3C.D'). There 
was little change in the PDTs of either DU-145 or LNCaP cells when using 
concentrations of 0.5, 1 or 2 pg/ml of AG650 or ActPSA. Although there was a 27.4% 
increase in the PDT of DU-145 cells using 2 pg/ml AG650, the difference was not 
significant most likely due to the large SEM (Figure 3A). Oppositely, there was a 13, 12 
and 17% decrease in PDT using 0.5, 1, and 2 pg/ml ActPSA, respectively (Figure 3BT 
For the LNCaP cells, we observed an increase in PDT when using 1 pg/ml of either 
AG650 or ActPSA, where the PDT was increased by 16 and 57%, respectively. 
However, the error was considerable on each of these measurements (Figure 3C.DL
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Figure 3: Effects of PSA on population-doubling time of DU-145 and LNCaP cells
DU-145 cells (A,B) were seeded at 1,000 cells/well and LNCaP cells (C,D) were seeded at 5,000 cells/well. 
After overnight adherence, AG650 PSA or ActPSA were added to the cells in fresh medium at 
concentrations of 0.5, 1 and 2 pg/ml. Cells were plated in triplicate per 96-well plate and were grown for 4 
days in the presence of PSA. The cell number was determined using Hoechst-DNA RFU standard curves. 
PDTs were determined using the slope of the cell number determined over days 2-4 of the growth curve. 
Error bars represent SEM of PDTs determined from 2 duplicate experiments, with 4 duplicate wells/day (n 
= 8).
Standard curves to relate DU-145 and LNCaP cell number to calcein-related 
fluorescence
The invasion and migration assays each used the hydrolysis of calcein AM and the 
resulting accumulation of cytoplasmic calcein fluorescence to determine the number of 
invaded or migrated cells. In order to correlate cell number to cytoplasmic calcein RFU 
in these experiments, standard curves were created for each the DU-145 and LNCaP cell 
lines. Cells were serially diluted and incubated with calcein AM to find the linear range
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correlating cell number with RFU. The standard curves for DU-145 and LNCaP cells are 
shown in Figure 4. For DU-145 cells, the linear range was found to be 98 -  12,500 
cells/well and for LNCaP cells, the linear range was found to be 198 -  12,500 cells/well, 
each using a linear regression standard curve (R  ̂> 0.99 for both cell types). It was found 
that one DU-145 cell produced 0.133 RFU while each LNCaP cell produced 0.299 RFU 

























Figure 4: Standard curves relating cell number to calcein fluorescence of LNCaP and DU-145 cells
DU-145 and LNCaP cells were serially diluted, plated in 96-well plates and incubated in “cell dissociation 
solution” with 2 pg/ml calcein AM for one hour. Calcein levels within the cells were measured by 
fluorescence at 520 nm using an excitation of 485 nm. Linear regression was used to create a standard 
curve relating RFU to cell number. DU-145 cells yielded 0.113 RFU/cell (R  ̂= 0. 9981) while LNCaP 
cells gave 0.299 RFU/cell (R  ̂= 0.9967). Error bars represent standard deviation from 2-8 duplicates.
Effects of exogenous PSA on DU-145 cell invasion and migration
To test the effects of exogenous PSA on invasion and migration, DU-145 and LNCaP 
ceils were seeded in transmembrane chambers and were allowed to traverse the 
membrane over 24 hours. Various conditions were used to test for invasive and 
migratory differences. Medium supplemented with either 0.5 or 10% FBS was used as a
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chemoattractant in the lower chamber of the invasion well. To test cell invasiveness, 
BME -  used as an in vitro simulated BM -  was employed at different concentrations to 
coat the transmembranes in the chambers and act as a barrier to all but invasive cells. For 
the more invasive DU-145 cells, BME concentrations ranging from 0.1 -  0.05 mg 
BME/well were used and for the less invasive LNCaP cells, 0.05 -  0.01 mg BME/well 
were used.
Using 10% FBS-supplemented medium as a chemoattractant for DU-145 cells, an 
average of 693 ± 65 cells were able to invade through 0.1 mg BME/well and an average 
of 2343 ± 336 cells were able to invade through 0.05 mg BME/well (Figure 5). This 
corresponds to 1.4 and 4.7% of the 50,000 cells seeded, respectively. No significant 
changes were seen in the invasion of DU-145 cells using concentrations of AG650 or 
ActPSA between 0.5 -  2 pg/ml. Although there appeared to be a dose-dependent 
decrease in invasion of DU-145 cells using ActPSA and invasion through 0.05 mg 
BME/well, these results were not statistically significant (p values using Student’s t-test > 
0.05). Cell migration of DU-145 cells using 10% FBS as a chemoattractant gave RFU 
readings beyond the linear range of the standard cell curve relating calcein RFU to cell 
number, therefore were not interprétable (i.e. cell number > 12,500/well). Unfortunately, 
RFUs determined for the invasion of LNCaP cells using this method were below the 
linear range of the standard cell curve, therefore cell numbers were not quantifiable (i.e. 
cell number < 198/well).
Since no significant changes were seen in the invasion or migration of DU-145 
cells, the assays conditions were changed. In order to lower possible enzymatic 
inhibitory effects on PSA by protease inhibitors potentially present in FBS, its
63
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
concentration was decreased from 10% (v/v) in medium to 0.5% when used as a 
chemoattractant for the cells. Also, only the lower concentrations of 0.05 mg BME/well 
for DU-145 cells and 0.01 mg BME/well for LNCaP cells were used in the invasion 
assays with 0.5% FBS supplemented medium as a chemoattractant. As well, the 
maximum concentration of PSA used was increased to 5 pg/ml ActPSA, in order to 
increase the possibility of PSA having an effect on invasion or migration. AG650 was 
not used in these assays due to potential aberrant results from impurities. DU-145 cells 
showed an average of 1292 ± 85  cells/well invaded and 953 ± 139 cells/well migrated 
when growth media supplemented with 0.5% was used as a chemoattractant (Figure 6). 
This corresponds to 2.6% of cells invaded and 1.9% of cells migrated from the 50,000 
cells plated. There was no significant difference in invasion or migration of DU-145 
cells using 2 or 5 pg/ml ActPSA. Although there appears to be a dose-dependent 
decrease in invasion of DU-145 cells using 2 - 5  pg/ml ActPSA, these results were not 
statistically significant (p > 0.05). Similar to the assays using 10% FBS as a 
chemoattractant, the RFU values determined for the invasion as well as the migration of 
LNCaP cells was below that seen for the linear range of the calcein RFU standard cell 
curve, and therefore cell number was not quantifiable.
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Figure 5: Effect of exogenous PSA on the invasion of DU-145 cells using 10% FBS as a
chemoattractant
DU-145 cells were seeded at 5X10“* cells/well in SF medium and incubated for 24 hours in invasion 
chambers with either 0.1 or 0.05 mg BME/well. Varying concentrations of AG650 or ActPSA were added 
to each well. The bottom wells of the invasion chambers contained DU-145 growth medium supplemented 
with 10% FBS. After 24 hours, the relative amount of cells on the underside of the membrane (i.e. invaded 
cells) were determined using the relative fluorescence units (RFU) from hydrolysed calcein AM, 
representing cell number. Error bars represent SEM from 2 separate experiments, with cells seeded in 
triplicate.
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Figure 6: Efleet of exogenous ActPSA on the invasion and migration of DU-145 cells using 0.5% FBS
as a chemoattractant
DU-145 cells were seeded at 5X10'* cells/well and incubated for 24 hours in invasion chambers with either 
0.05 mgBME/well or lacking BME. Varying concentrations of ActPSA were added to each well. The 
bottom wells of the invasion chambers contained DU-145 growth medium supplemented with 0.5% FBS. 
After 24 hours, the relative amount of invaded cells were determined using the relative fluorescence units 
(RFU) from hydrolysed calcein AM, representing cell number. Error bars represent SEM from 2-3 separate 
experiments, with cells seeded in duplicate or triplicate.
Creation o f the modpSTHMppPSA plasmid
Since the exogenous sources of PSA may not have been purely enzymatically active 
forms of PSA -  as suggested by the multiple bands show in Western blot analysis (Figure 
i )  -  we decided to transfect DU-145 cells with cDNA for the PSA gene. A plasmid 
vector system using the CMV promoter for high-level constitutive gene expression was 
chosen for the insertion of PSA cDNA.
In order to create a plasmid with the full length PSA gene, PCR primers were 
used that amplified a region of the pcDNAS.PSA corresponding to the first 350 bp of the 
PSA gene. The 31 bp forward primer “Sense pcDNA3.PSA prepro primer A+C” 
5’GTTGAGCTAGCACC^TGTGGGTCCCGGTTGT3’ contained an Nhel restriction 
site (underlined), and a transcription initiation site (italicized). The 21 bp reverse primer
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“as new A pcDNAS.PSA prepro primer” 5’CATCACCTGGCCTGAGGAATC3’ was a 
reverse compliment of the PSA coding sequence from 325 -  346 bp downstream of the 
initiation site. A PCR reaction with these two primers was run using the conditions in 
Table 1 with an annealing temperature of 59 °C. The product was run on an agarose gel, 
the -360 bp fragment (Figure 7A) was excised from the gel and the DNA was isolated. 
The ends of the isolated PCR product were then cleaved using a double digest with Nhel 
and Clal restriction enzymes, leaving 4 bp overhangs on the 5’ and 3’ ends, respectively. 
The initial coding sequence for IgK and a portion of the PSA coding region in the plasmid 
modpSecTagPSA was removed using the restriction enzymes Nhel and Clal. Each 
digestion product was run on an agarose gel, excised and gel-extracted; the correct PCR 
product digest was -333 bp and the modpSecTagPSA digest product was -6  kb in size 
(Figure 7B). These digest products were ligated overnight and the ligation product was 
used to transform competent JM109 E. coli. A double restriction digest with Ndel and 
Hindin was performed on the isolated plasmid DNA to confirm the presence of the 
“preproPSA” (Figure 7 0 . The insert was verified by forward DNA sequencing using the 
primer “Sense pcDNA3.PSA prepro primer A+C” and reverse DNA sequenced using the 
“as new A pcDNA3.PSA prepro primer”, each for -Ikb. A diagram explaining the 
components of this plasmid is shown in Figure 10.
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Figure 7: Creation o f the modpSTHMppPSA vector
A) PCR reaction using pcDNAS.PSA as a template and the primers "Sense pcDNAS.PSA prepro primer 
A+C" and "as new A pcDNAS.PSA prepro primer”. The amplified region of ~S60 bp is shown.
B) Clal and Nhel double digestion of the modpSecTagPSA plasmid. The digestion product bands were 
observed at -6.1 kb and 400bp (faintly).
C) Ndel and Hindlll double digest to verify a positive JM109 clone with the modpSTHMppPSA plasmid. 
The digest product bands of modpSecTagPSA observed at -S.5 kb, 2.4 kb and 5 IS bp were compared to 
the digestion product bands of modpSTHMppPSA at -S.5 kb and 2.7 kb.
Creation o f the modpSTHMprePSA plasmid
Not only did we want to express flill-length PSA cDNA, we also wanted to create a 
vector system that would allow expression of enzymatically active PSA without the need 
for extracellular activation by other proteases. To do this, we created a deletion mutation 
of the “pro” region to allow mature PSA to be secreted outside of the cell instead of as 
the zymogen proPSA. The deletion of the “pro” sequence was accomplished such that 
the secretory “pre” sequence would be in coding sequence with the mature PSA 
sequence. Proper cleavage of the “pre” region from the prePSA deletion mutant would 
theoretically yield the secretion of enzymatically active PSA.
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To create a plasmid lacking the “pro” region of the PSA gene, a deletion mutation 
was made from modpSTHMppPSA (a flow diagram of this process is shown in Figure 8). 
First, two separate PCR reactions were used that flanked the 21 bp “pro” region. The 
reaction “PCR 1” amplified the 322 bp region from the middle of the CMV promoter to 
the end of the “pre” region of the modpSTHMppPSA plasmid. This was accomplished 
by a PCR reaction with an annealing temperature of 58 °C using the sense primer “sense 
b modpSTHMppPSA” 5’GGCGTGGATAGCGGTTTGAC3’ and the anti-sense primer 
“as mid modpSTHMppPSA”
y CACTCCCAGCCYCCCACAATAGCACCAATCCACGTCACGG3\ The underlined 
region compliments the first 20 bp of the mature PSA sequence, and the italicised region 
compliments the last 20 bp of the “pre” region. The second PCR reaction, “PCR 2”, 
amplified the 332 bp region of modpSTHMppPSA from the beginning to the middle of 
the mature PSA coding sequence. The “PCR 2” reaction was carried out using the 
conditions in Table 1, with an annealing temperature of 59 °C, using the anti-sense 
primer “anti-sense b modpSTHMppPSA” 5 ’ CGGAGCAGCATGAGGTCGTG3 ’ and the 
sense primer “s mid modpSTHMppPSA”
5’CCGTGz(CGrGa47TGG7GC7ATTGTGGGAGGCTGGGAGTG3’. Again, the 
italicised region compliments the last 20 bp of the “pre” region and the underlined region 
compliments the first 20 bp of the mature PSA sequence. The products of the “PCR 1” 
and “PCR 2” reactions were run on an agarose gel and the 322 bp and 332 bp bands, 
respectively, (Figure 9A) were extracted from the gel.
The next step was to attach the products of “PCR 1” and “PCR 2” into a linear 
DNA sequence. To attach the two fragments (360 ng “PCR 1” and 420 ng “PCR 2”) both
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were added together in a PCR reaction using an annealing temperature of 59 °C together 
with primers “sense b modpSTHMppPSA” and “anti-sense b modpSTHMppPSA”. This 
“PCR 3” reaction takes advantage of the overlapping regions created from “as mid 
modpSTHMppPSA” and “s mid modpSTHMppPSA”, allowing the “PCR 1” and “PCR 
2” products to combine. The “PCR 3” product was run on an agarose gel and the -614 
bp-sized band (Figure 9B) gel isolated and 0.58 mg of the isolated fragment was 
subjected to a double restriction digestion with Nhel and Clal. This product was run on 
an agarose gel and the -310 bp-sized band was gel extracted. The plasmid 
modpSTHMppPSA was also subjected to a double restriction digest with Nhel and Clal 
and the digestion product run on an agarose gel and the 6.0 kb sized band (Figure 9 0  
was extracted from the gel. The 310 bp fragment from the “PCR 3” product digestion 
and the 6.0 kb fragment from the modpSTHMppPSA were ligated together. This ligation 
product was used to transform competent JM109 E. coli, and a double digest with Ndel 
and Clal was performed on the isolated DNA to confirm the presence of the “prePSA” 
insert in the modpSTHMprePSA (Figure 9D). The insert was verified by forward DNA 
sequencing using the primer “Sense pcDNA3.PSA prepro primer A+C” and reverse DNA 
sequenced using the “as new A pcDNA3.PSA prepro primer”, each for -Ikb. A diagram 
explaining the components of this plasmid is shown in Figure 10.
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Figure 8: Schematic representation of the PCR based deletion of "pro" region of PSA gene
See the section “Creation of the modpSTHMprePSA plasmid” for details.
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Figure 9: Creation of the modpSTHMprePSA vector
A) Two PCR reactions that surround the “pro” region of the PSA gene. PCR T. The primers “sense b 
modpSTHMppPSA” and “as mid modpSTHMppPSA” were used to amplify the band at -322 bp; PCR 2; 
The primers “s mid modpSTHMppPSA” and “anti-sense b modpSTHMppPSA” were used to amplify the 
-332 bp band.
B) The PCR 3 product was amplified using PCR products of PCR 1 and PCR 2 as well as the primers 
“sense b modpSTHMppPSA” and “anti-sense b modpSTHMppPSA” to obtain a -614 bp band.
C) Nhel and Clal double restriction enzyme digestions. PCR 3; digest produced bands at -310 bp and 253 
bp (50 bp fragment not seen). ModpSTHMppPSA: produced bands at -  6 kb and 380 bp.
D) Ndel and Clal double restriction enzyme digestions to verify a positive JM109 clone with the 
modpSTHMprePSA plasmid. The modpSTHMprePSA digest produced bands at -3.5 kb, 2.1 kb and 722 
bp. As a control, modpSTHMppPSA digest gave bands at -3.5 kb, 2.1 kb and 743 bp.
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Figure 10: Schematic diagrams of CMV promoter vector systems used
These pictures represent each respective plasmid in their circularized forms. Extensions above plasmid 
circle represent the multiple cloning site of the vector with the different versions of the PSA gene inserted. 
Arrows represent enzymatic digestion sites for the designated restriction enzymes. Vector components; 
PcMv Human cytomegalovirus immediate-early promoter/enhancer for high-level gene
expression
T7 T7 promoter/priming site for in vitro transcription
IgK leader Murine IgK-chain leader sequence for secretion o f fusion protein
TAA Bovine growth hormone polyadenylation signal for efficient transcription termination and
polyadenylation of mRNA 
fl ori fl origin allows rescue of single stranded DNA in bacteria
Psv4o PSV40 early promoter and origin allows efficient, high-level expression of the
hygromycin resistance gene and episomal replication in cells expressing the SV40 large T 
antigen
Hygromycin Hygromycin resistance gene (Hygromycin B-phosphotransferase) that allows for
selection of stable transfectants 
SV40 SV40 polyadenylation signal that allows for efficient transcription termination and
polyadenylation of mRNA 
pUC pUC origin that allows for high-copy number replication and growth in E. coli
Ampicillin Ampicillin resistance gene (p-lactamase) that allows for selection in E. coli
*(all vector diagrams were modified from Invitrogen)
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Stable transfection of DU-145 cells with modpSTHMppPSA and 
modpSTHMprePSA
DU-145 cells were transfected separately with either modpSTHMppPSA or 
modpSTHMprePSA plasmid DNA, using the methods described in “Standard stable 
clone creation using electroporation”. Electroporation parameters used (with a 
capacitance of 50 pF) are shown in Table 4. Some cells were transfected with linearized 
plasmid DNA to increase the chance of a stable transfectants by controlling the site of 
plasmid cleavage before integration into the DU-145 genome. modpSTHMppPSA and 
modpSTHMprePSA plasmids were linearized using the restriction enzyme Bglll and the 
linearized plasmids were purified. This digestion results in a single cut in each plasmid 
within a non-coding region upstream of the CMV promoter. As a vector control, 
modpSecTagPSA was digested with both Nhel and Xbal restriction enzymes to remove 
the entire PSA gene. The resulting linearized truncated plasmid was run on an agarose 
gel and the extracted band at -5.5 kb was used in electroporation for the DU-noPSA 
clones. Transfected cells were seleeted using growth media supplemented with 200 
pg/ml hygromycin B as a selective agent, a concentration that resulted in -5% cell 
survival after 5 days, as determined by previous studies in our lab. Nomenclature of each 
subclone and the number of colonies isolated is shown in Table 4.
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modpSTHMppPSA 3 pg 4X  10® No lOOOV then 2000V D-ppPSA 6
modpSTHMppPSA 3 pg 4X10® No 1500 V D-ppPSA
modpSTHMppPSA -1-5 pg 4X10® Bglll 1500 V DU-ppPSA 5
modpSTHMprePSA 3 pg 4X  10® No 1000VX2 D-prePSA 1modpSTHMprePSA 3 pg 4X  10® No 1500 V D-prePSA
modpSTHMprePSA -1-5 pg 4X10® Bglll 1500 V DU-prePSA 7
modpSecTagPSA -1-5 pg 4X10® Nhel and Xbal 1500 V DU-noPSA 7
Expression of PSA from stable and transient DU-145 transfects 
To screen the stable D(U)-ppPSA and D(U)-prePSA clones for secretion of PSA, CM 
was analyzed using Western blotting. A band corresponding to PSA was only visible 
from two of the ppPSA clones: D-ppPSA-1 (Figure llA l and DU-ppPSA-2 (Figure 1 IB). 
However, PSA in the CM of eaeh of these clones was only detected from cells growing 
the second passage after transfection. All subsequent passages of each clone were 
negative for PSA as determined by Western blot analyses, even after eoneentration of SF 
CM as much as 25 times using a 10 kDa eut-off filter. PSA was not detectable in the CM 
of any of the D(U)-prePSA clones, regardless if the CM was concentrated.
Since the presence of PSA was not observed in the D(U)-prePSA CM, transient 
transfeetions were performed to assess whether the modpSTHMprePSA was able to 
produee PSA within DU-145 eells. DU-145 cells were transiently transfected with 1 and 
2 pg of modpSTHMprePSA using lipofectamine. Western blot analyses were performed 
on 2 and 3 day CM (Figure 11 Cl. PSA was detectable using both amounts of plasmid on 
days 2 and 3 in a plasmid dose-dependent manner. This proved that the prePSA deletion
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mutant encoded in the modpSTHMprePSA plasmid could be expressed by DU-145 cells 
and that this form of PSA was detectable using Western blotting.
B
Figure 11: Expression of PSA using the CMV promoter system
Western blots showing PSA from stably transfected clones (A,B) and transient transfections (C,D). AG650 
PSA: 20 ng of protein was added per well. A+B) 33 pi of 3 day serum-supplemented CM from D-ppPSA-1 
(A) or DU-ppPSA-2 (B) the 2”® passage after transfection. C) CM of DU-145 cells transfected with 1-2 pg 
modpSTHMprePSA, which was conditioned for 2 or 3 days post transfection. 33 pi of CM was loaded per 
lane.
Stable Transfection o f DU-145 cells with pERV3
Since stable clones of DU-145 cells transfected with modpSTHMppPSA and 
modpSTHMprePSA did not show stable expression of PSA, we decided to create clones 
of DU-145 cells that could express ppPSA and prePSA in an inducible manner. A double 
transfection system was chosen that used a combination of a plasmid encoding a PonA 
inducible transcriptional activator (pERV3) and a cloning vector with a binding site for 
the transcription activator (pEGSH). Diagrams for these plasmids are shown in Figure 
15. Stable transfection with pERV3 is this first step in this system, in order to obtain a 
cell line that expresses VgEcR, a transcriptional activator that is turned on by PonA.
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DU-145 cells were electroporated with pERV3 using the electroporation 
parameters shown in Table 5. For some transfections, the restriction enzyme PstI was 
used to linearize the plasmid pERV3. This results in a single cut in the region upstream 
of the CMV promoter; the linearized plasmid was purified and used in electroporation to 
maximize the chances of obtaining a stable clone. Transfectants were grown in medium 
containing 400 pg/ml G418 as a selective agent. This concentration was selected because 
it was the lowest concentration that resulted in 5% of cells surviving in 5 days (Figure 











Concentration of G418 (pg/ml)
ooo 4000-500
Figure 12: Cytotoxicity of G418 in DU-145 ceils
DU-145 cells seeded at 400 cells/well were treated with varying concentrations of G418. After a period of 
5 days, DNA content/well was determined using the Hoechst-DNA assay and compared to control cells. 
Error bars represent SEM of 8 replicates per experiment fi’om 2 identical experiments.
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pERV3 3 pg 4X  10* No 1500 V DU-pERV3 A 9
pERV3 6pg 4X  10* No 1500 V DU-pERV3 B 9
pERV3 7.6 pg 4X  10* PstI 1500 V DU-pERV3 C 9
Selection o f a stable DU-pERV3 clone using the luciferase assay 
In order to select a stable DU-pERV3 clone, each clone was subjected to the luciferase 
assay. To accomplish this, cells were transiently transfected with the pEGSH-luc plasmid 
-  a pEGSH construct encoding the luciferase gene -  and cell lysates were assayed for 
lucifertise activity. A clone positive for VgEcR expression from the pERV3 plasmid 
should show an increasing amount of luciferase activity with an increasing amount of 
PonA. This was observed for the clone DU-pERV3 C3, a subline transfected with 
linearized pERV3. The DU-pERV3 C3 clone showed a useful level of induction (Figure 
131 while all other DU-pERV3 clones tested showed similar induction patterns to the 
parent DU-145 cells (data not shown). There was also an increasing level of induction in 
the DU-pERV3 C3 cells as the amount of transiently transfected pEGSH-luc decreased. 
The percent increase of RLU over control when induced by 10 pM PonA was 255 ± 108, 
674 ±321, and 1875 ± 836% when transiently transfected with 7.5, 1.0 and 0.1 pg 
pEGSH-luc respectively. This is strong evidence for stable expression of the VgEcR 
transcription activator, because when less pEGSH-luc is used in the transient transfection, 
there will be a lower copy number of plasmids per cell. Since there are fewer plasmids 
per cell, there is a greater ratio of VgEcR proteins to pEGSH-luc plasmids within each 
cell to be able to regulate the luciferase gene. Therefore, as plasmid copy number goes
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down, the percent induction goes up. The DU-pERV3 C3 clone was chosen for 
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Figure 13: Luciferase assay of pEGSH-luc transfected DU-pERV3 C3 and DU-145 cells
DU-pERV3 C3 and DU-145 cells (5X10* each) were transiently transfected with the amount of pEGSH- 
luc shown. Cell lines were incubated overnight post transfection in 0 pM or 10 pM PonA. Cell lysates 
were harvested and a luciferase assay done to determine the level of luciferase activity in the cells. RLU 
values of the cells treated with 10 pM PonA were compared as a percentage of the RLU from the solvent 
control treated cells. Error bars represent SEM of 2-3 identical experiments.
79
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Creation o f the pEGSHppPSA plasmid
To insert the full-length preproPSA cDNA sequence into the pEGSH plasmid, primers 
were used that amplified an 879 bp segment containing the preproPSA gene from the 
modpSTHMppPSA. The 33 bp forward primer “s BamHI pmodSTHM to pEGSH” 
5’GTTGAGGATCCGCCTCCTTGTGGGTCCCGGTTG3’ contained a BamHI site 
(underlined) and a modified Kozak sequence (italicized). The 22 bp reverse primer “as 
BamHI pmodSTHM to pEGSH” 5’GATGGTCGACGGCGCTATTCAG3’ was reverse 
complimentary to a region outside of the Xhol restriction site on the modpSTHMppPSA 
plasmid, downstream of the preproPSA gene stop codon. The PCR reaction was run 
using the conditions in Table 1 with an annealing temperature of 60.5 °C. The product 
was run on an agarose gel, the -879 bp fragment (Figure 14A) was excised from the gel 
and the DNA was isolated. The ends of the isolated PCR product were then removed 
using a double digest with BamHI and Xhol restriction enzymes. Similarly, pEGSH was 
also digested using BamHI and Xhol (both in the MCS) to allow insertion of the PCR 
product. Each digestion product was run on an agarose gel, excised and gel-extracted; 
the correct PCR product digest was -802 bp and the pEGSH digest product was -4.8 kb 
in size (Figure 14B). These digestion products were ligated overnight and the ligation 
product was used to transform competent JM109 E.coli. A restriction digest with PstI 
was performed on the plasmid DNA to confirm the presence of the “preproPSA” insert in 
the pEGSH plasmid (Figure 14C). The insert was verified by forward DNA sequencing 
using the primer “s BamHI pmodSTHM to pEGSH” and reverse sequencing using the 
primer “as new C pcDNA3.PSA prepro primer” each for -Ikb. A diagram explaining the 
components of this plasmid is shown in Figure 15.
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Figure 14: Creation of the pEGSHppPSA and pEGSHprePSA Vectors
A) PCR products of amplified PSA genes fi-om the different modpSTMH plasmids. ppPSA PCR: 
amplified preproPSA fi-om modpSTHMppPSA using the primers “s BamHI pmodSTHM to pEGSH” and 
“as BamHI pmodSTHM to pEGSH” to create an -879 bp band; prePSA PCR: amplified prePSA from 
modpSTHM using the primers “s BamHI pmodSTHM to pEGSH” and “as BamHI pmodSTHM to 
pEGSH” to create an -858 bp fragment.
B) BamHI and Xhol double restriction enzyme digestion of pEGSH and PCR products for ligation. 
pEGSH digest: gave a band at -4.8 kb; ppPSA PCR digest: gave a band at 801 bp; prePSA digest: gave a 
band at 780 bp.
C) PstI restriction enzyme digestion to verify positive JM109 clones. ppPSA miniprep digest: gave bands 
at -3.7 kb, 1.5 kb and 393 bp; prePSA digest: gave bands at -3.7 kb, 1.5 kb, and 393 bp.
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Creation o f the pEGSHprePSA plasmid
To insert the prePSA gene into the pEGSH plasmid, primers were used to amplify an 858 
bp segment containing the prePSA gene in modpSTHMprePSA. The 33 bp forward 
primer “s BamHI pmodSTHM to pEGSH”
5 ’ GTTGAGGATCCGCCTCC4 rGTGGGTCCCGGTTG3 ’ contained a BamHI site 
(imderlined) and a modified Kozak sequence (italicized). The 22 bp reverse primer “as 
BamHI pmodSTHM to pEGSH” 5’GATGGTCGACGGCGCTATTCAG3’ was reverse 
complimentary to a region outside of the Xhol restriction site on the modpSTHMprePSA 
plasmid, downstream of the prePSA gene stop codon. The PCR reaction was run using 
the conditions in Table 1 with an annealing temperature of 60.5 °C, and the product was 
run on an agarose gel. The -858 bp fragment (Figure 14A) was excised from the gel and 
the DNA was isolated. The ends of the isolated PCR product were then removed using a 
double restriction enzyme digest with BamHI and Xhol. Similarly, pEGSH was also 
cleaved in the MCS with BamHI and Xhol restriction enzymes to allow insertion of the 
PCR product. Each digestion product was run on an agarose gel, excised and gel- 
extracted; the correct PCR product digest was -776 bp and the pEGSH digest product 
was -4.8 kb in size (Figure 14B). These digest products were ligated overnight and the 
ligation product was used to transform competent JM109 E.coli. A restriction digest with 
PstI was performed on the plasmid DNA to confirm the presence of the “prePSA” insert 
in the pEGSH plasmid (Figure 14C). The insert was verified by forward DNA 
sequencing using the primer “s BamHI pmodSTHM to pEGSH” and reverse sequencing 
using the primer “as new C pcDNA3.PSA prepro primer”, each for -Ikb. A diagram 
explaining the components of this plasmid is shown in Figure 15.
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Figure 15: Schematic diagrams of Complete Control® vectors used*
These pictures represent each respective plasmid in their circularized forms. Extensions above plasmid 
circle represent the multiple cloning site of the vector with the different versions of the PSA gene inserted. 
Arrows represent enzymatic digestion sites for the designated restriction enzymes. Vector components**:
RXR retinoid-X-receptor ORF
1RES internal ribosome entry site
VgEcR synthetic VP 16-glucocorticoid/ecdysone receptor ORF
TKpA HSV-thymidine kinase polyA signal
neo/kan neomycin/kanamycin resistance ORF
Pbla b/a promoter
PTK HSV-thymidine kinase promoter
5 X E/GRE 5 X ecdysone/glococorticoid responsive elements
3XSP1 3 X Spl binding sites
mHSP minimal heat shock promoter
FLAG FLAG tag
* (all vector diagrams were modified fi-om Stratagene)
** (for explanation of the functions of the following components, see Figure 10: fl ori, SV40 pA, P CMV, 
pUC ori, hygromycin, P SV40)
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Stable transfection of DU-pERV3 C3 Cells with pEGSHppPSA, 
pEGSHprePSA and pEGSH
DU-pERV3 C3 cells were electroporated with pEGSH, pEGSHppPSA, and 
pEGSHprePSA using the parameters shown in Table 6. Some cells were transfected with 
linearized plasmid DNA to increase the chance of a stable transfectants by controlling the 
site of plasmid cleavage before integration into the DU-145 genome. The restriction 
enzyme Asel was used to linearize pEGSHppPSA and pEGSHprePSA prior to 
transfection. This enzyme cleaves the plasmid only once in the middle of the ampicillin 
resistance portion of the gene. As a vector control, DU-pEVR3 C3 cells were transfected 
with an empty pEGSH vector.
To select for plasmid positive clones, transfectants were grown in medium 
containing 400 pg/ml G418 and 100 pg/ml hygromycin B as selective agents. The 
concentration of G418 was chosen as this was the concentration used to select for DU- 
pERV3 clones. The concentration of hygromycin B was selected as it was the lowest 
concentration that resulted in ~5% cell survival in 5 days when 400 pg/ml G418 was 
already present (Figure 16). After 2 weeks growth of the transfected DU-pERV3 C3 
cells, the hygromycin B concentration was increased to 150 pg/ml to increase selective 
pressure for the pEGSH plasmid constructs. Nomenclature of each subclone and the 
number of clones isolated is shown in Table 6.
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Table 6: Electroporation Parameters for Transfecting pEGSH, pEGSHppPSA and pEGSHprePSA











pEGSHppPSA 3 pg 2X  10* Asel 1500 V, then 1000 V
DU-pERV3 
C3 ppPSA 18
pEGSHprePSA 3 pg 2X  10* Asel 1500 V, then 1000 V
DU-pERV3 
C3 prePSA 18








100 200 300 500-500
Concentration Hygromycin B (pg/ml)
Figure 16: Cytotoxicity of hygromycin B with 400 (^ m l G418 in DU-pERV3 C3 cells
DU-pERV3 €3 cells seeded at 400 cells/well were treated with varying concentrations of hygromycin B 
with a constant concentration of 400 pg/ml G418. After a period of 5 days, DNA content/well was 
determined using the Hoechst-DNA assay and compared to control. Error bars represent SEM of 8 
replicates per experiment ft-om 2-4 identical experiments.
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Detection of recombinant PSA cDNA in genomic DNA of DU-pERV3 C3 
ppPSA/prePSA subclones
In order to detect the presence of an integrated portion of the recombinant PSA cDNA 
gene in the genome of the DU-pERV3 C3 ppPSA and prePSA subclones, a PCR reaction 
was used to differentiate the introduced PSA cDNA from genomic klk3 DNA. Genomic 
DNA was isolated from each ppPSA/prePSA subclone, as well as the control EGSH 
subclones, the parent DU-145 line and the LNCaP cell line. A 379 bp region of the PSA 
cDNA was amplified from the location 225 -  603 bp downstream of the start codon. To 
differentiate between integrated PSA cDNA and the naturally occurring klk3 gene, 
primers were designed that surrounded the fourth intron of the genomic PSA encoding 
gene that spans 171 bp. The amplification of the klk3 gene segment extends across 550 
bp compared to an amplification of integrated PSA cDNA which spans 379 bp. The 
forward primer “PSA sense B 225-246” 5 GGTCGGCACAGCCTGTTTCATC3' 
corresponds to bases 225 -  246 downstream of the start codon of PSA cDNA, and the 
reverse primer “PSA anti-sense B 582-603” 5’GCGTCCAGCACACAGCATGAAC3’ 
corresponds to the reverse compliment of bases 582 -  603 downstream of the start codon 
in PSA cDNA. A PCR reaction was run for each clone using the conditions in Table 1 
with an annealing temperature of 60 ®C and an extension time of 30 seconds. The results 
of the PCR amplification of genomic DNA from DU-145, LNCaP and DU-pERV3 C3 
subclones transfected with pEGSH constructs are shown in Figure 17. As expected, PCR 
amplification of all of the DU-pERV3 C3 ppPSA (with the possible exeeption of 
ppPSA2) and DU-pERV3 C3 prePSA genomic DNA showed the presence of the klk3 
gene with a band at -550 bp (upper band) as well as the presence of the PSA cDNA with
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a band at -379 bp (lower band). Amplification using the DU-145, LNCaP or DU-pERV3 
C3 pEGSH genomic DNA produced only the single band at -550 bp and did not show a 
band at 379 bp, indicating the absence of PSA eDNA. These results verify that the 
portion of the PSA cDNA from 225 -  603 bp downstream of the start codon was 
integrated into the genome of the DU-pERV3 C3 ppPSA and prePSA subclones.
^  ppt
pr«14
Figure 17: Detection of PSA cDNA inserted into genomic DNA
Genomic DNA from DU-145, LNCaP and DU-pERV3 C3 subclones transfected with pEGSH constructs 
were subjected to PCR amplification. Primers used spanned a 379 bp region of PSA cDNA (lower band), 
and 550 bp region in the wild type hK3 gene (upper band), pp#: refers to DU-pERV3 C3 ppPSA 
sublcones; pre#: refers to DU-pERV3 C3 prePSA subclones; E#: refers to DU-pERV3 C3 pEGSH 
subclones; M: molecular weight markers of 600 bp (upper), 500 bp (middle), 400 bp (lower).
Induction o f PSA secretion from DU-pERV3 C3 ppPSA/prePSA subclones 
using ponasterone A
Afl:er determining that all of the DU-pERV3 C3 ppPSA/prePSA subclones contained 
PSA cDNA in their genome, clones were tested for their ability to secrete PSA when 
induced with PonA. A total of three DU-pERV3 C3 ppPSA subclones (pp6, pp9 and
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ppl3), two DU-pERV3 C3 prePSA subclones (pre2 and pre7) were chosen for ftirther 
study. These subclones were chosen as, upon initial screening, they showed high 
expression of recombinant PSA when induced with 10 pM PonA. As well, two DU- 
pERV3 C3 pEGSH subclones (E2 and E3) were chosen randomly for use as vector 
control cells. To induce PSA expression, each subclone was seeded in selective growth 
medium, and the next day the medium was changed to SF medium, containing either 10 
pM PonA or a solvent control. Cells were allowed to condition the SF medium for 4 -  5 
days, then the CM was concentrated using 10 kDa cut-off filters and assayed for PSA 
levels using Western blot analysis. Each of the pp6, pp9, ppl3, pre2 and pre7 subclones 
tested showed PSA secretion into the medium regardless of the presence of PonA (Figure
18). The pp-subclones produced a PSA band at 29 kDa while the pre-subclones produced 
a band for PSA at 28 kDa. No PSA was detected in CM obtained from the vector control 
E2 or E3 cells.
Although the DU-pERV3 C3 ppPSA and DU-pERV3 C3 prePSA subclones did 
secrete PSA in the absence of PonA, there were marked increases in the level of PSA 
secretion ranging from 132.5 -  280.2% when induced by 10 pM PonA (Table 7). The 
levels of PSA secreted from the DU-pERV3 C3 ppPSA cells ranged from 0.119 -  0.461 
ng/ml/1 O^cells/day and the levels of PSA secreted from the DU-pERV3 C3 ppPSA cells 
ranged from 0.034 -  0.218 ng/ml/1 O^cells/day. These values ranged from -18 -  250 fold 
lower than secreted by LNCaP cells, which produce 8.6 ±3.5 ng/ml/1 O^cells/day.
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Figure 18: Western blot showing PSA expression from DU-pERV3 C3 ppPSA and DU-pERV3 C3
prePSA subclones
Western blotting was used to determine relative levels of PSA secretion between PonA-induced and solvent 
control cells. SF conditioned media was collected from DU-pERV3 C3 ppPSA/prePSA/EGSH subclones 
after a period of 4 -  5 days in the presence of 10 pM PonA or a solvent control. CM was concentrated with 
a 10 kDa cut-off filter and media loaded in each individual gel was standardized to cell number. Each 
individual blot represents the difference between control and 10 pM PonA induced, but do not relate 
relative PSA levels between the clones.
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Table 7: PSA secretion level and percent PonA-induction using densitometry of Western blotting of 
DU-pERV3 C3 ppPSA/prePSA conditioned media
10 pM PonA Induced 
Subclone
Secreted PSA Level 
(ng/ml/1 O^cells/day) *
% Secreted PSA 
(untreated control)
DU-pERV3 C3 ppPSA6 0.461 ± 0.072 236.7 ± 9.3
DU-pERV3 C3 ppPSA9 0.119 ±0.041 273.8 ± 104.0
DU-pERV3 C3 ppPSA13 0.145 ± 0.055 132.5 ±29.4
DU-pERV3 C3 prePSA2 0.034 ±0.010 280.2 ±39.5
DU-pERV3 C3 prePSA? 0.218 ±0.184 207.6 ± 38.3
LNCaP 8.6 ±3.5 -
*PSA levels were calculated using a linear regression standard curve created from densitometry of three 
ActPSA standards per Western blot ( 1 - 2 0  ng/lane). Cell number was determined on the day CM was 
collected. Error is represented as ± SEM from 2-3 measurements.
Enzymatic activity of conditioned media from DU-pERV3 C3 
ppPSA/prePSA/EGSH subclones on S-2586
In order to test for enzymatic activity of PSA secreted by each the DU-pERV3 C3 ppPSA 
and DU-pERV3 C3 prePSA subclones, conditioned medium was collected and 
concentrated. Cells were allowed to condition the medium for 5 days, and media was 
concentrated using a 10 kDa cut-off filter. As a control used to simulate the conditions 
for enzymatic activity of PSA in CM, ActPSA was diluted in SF DU-145 medium as a 
sample buffer and used as an enzymatic activity control. As well, to increase the chances 
of seeing small amounts of PSA activity, the concentration of S-2586 was increased from 
0.4 mM to 0.8 mM.
Activity of ActPSA on the substrate S-2586 was detectable at a concentration of 
10 pg/ml but not at 0.8 pg/ml. The levels of PSA in the concentrated CM were below the 
level detectable by this assay (Table 8). Furthermore, the concentrated CM from all of 
the DU-pERV3 C3 subclones showed activity on S-2586, regardless of TPCK 
concentration. Due to the low levels of PSA produced and the activity of concentrated
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DU-pERV3 C3 ppPSA/prePSA/EGSH media on the substrate, no correlation was seen 
between enzymatic cleavage of S-2586 and clones that secreted PSA.









10 pM PonA 








ActPSA’ 0.0020 - 0.0018 - 10,000 -
pp6 0.0062 0.0052 0.0089 0.0097 37 (54) 40.2 X
pp9 0.0036 0.0035 0.0083 0.0090 10(21) 30.8 X
ppl3 0.0245 0.0184 0.0225 0.0172 197 (378) 220 X
pre2 0.0049 0.0057 0.0051 0.0069 5(12) 51.7 X
pre7 0.0365 0.0482 0.0379 0.0490 32 (50) 220 X
E2 0.0330 0.0333 0.0332 0.0411 0 230 X
E3 0.0026 0.0027 0.0059 0.0042 0 35.5 X
Medium was conditioned by the various subclones and concentrated using a 10 kDa cut-off filter. AA^o /̂hr 
was calculated over 0 - 6  hours of activity. * ActPSA values are in AA405/hr/ngPSA/ml. All other values 
are in AA^o /̂hr. ** PSA concentration is reported as control and (10 pM PonA).
Population-doubling time analysis of DU-pERV3 C3 ppPSA/prePSA/EGSH 
subclones
The PDTs of each the DU-pERV3 C3 ppPSA, DU-pERV3 C3 prePSA and DU-pERV3 
C3 pEGSH subclones were analyzed to determine if any growth changes were apparent 
between the different PSA-expressing subclones. As well, since the DU-pERV3 C3 
ppPSA and DU-pERV3 C3 prePSA showed an increase in PSA expression levels with an 
increase of PonA, the growth differences were determined between PonA induced and 
control cells. Eaeh subclone was seeded in DU-145 medium containing solvent control, 
1 or 10 pM PonA for 5 days. Each day, the cell numbers were determined, and using the 
numbers from hours 72, 96 and 120, population-doubling times were calculated (Figure
19). PDTs did not vary significantly for any of the cell lines using different 
concentrations of PonA, nor was there any significant variance in the PDT between the
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Figure 19: Population-doubling times of DU-pERV3C3ppPSA, DU-pERV3C3prePSA and DU 
pERV3C3pEGSH subclones with varying amounts of PonA
Population-doubling times for DU-pERV3C3ppPSA, DU-pERV3C3prePSA and DU-pERV3C3pEGSH 
subclones were determined using linear regression of the growth curve over 72-120 hours. Error bars 
represent SEM from PDTs determined from 2 identical experiments.
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clones (p > 0.05). Although the PDTs for pp9 using 1 and 10 |j,M PonA were 133.4% 
and 134.3% higher than that of the 0 pM PonA control respectively, this difference is not 
significant probably due to the relatively large variance.
Standard curves to relate pp6, pre2 and E3 cell number to calcein related 
fluorescence
In order to accurately measure the number of invaded or migrated cells, standard curves 
relating calcein RFU to cell number were created for the pp6, pre2, and E3 clones. Each 
subclone was serially diluted and incubated with calcein AM to find the linear range 
correlating cell number with RFU. The standard curves for pp6, pre2 and E3 are shown 
in Figure 20. The three subclones tested showed a near identical correlation of cell 
number to RFU. For all cells, the linear range was found to be 98 -  12,500 cells/well, the 
same as for DU-145 cells. It was found that one pp6 cell produced 0.157 RFU, one pre2 
cell produced 0.150 RFU, and one E3 cell produced 0.150 RFU (R  ̂> 0.99 for all three 
subclones). These standard curves were used to calculate the number of cells in 
migration/invasion assays. To calculate the cell number of a subclone for which there 
was no standard curve, a standard curve firom another subclone of the same type was used 
(i.e. to calculate pp9 or ppl3 cell number, the standard curve created for pp6 was used).
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Figure 20: Standard curves relating cell number to calcein fluorescence of pp6, pre2 and £3  cells
pp6, pre2 and E3 cells were serially diluted, seeded in a 96-well plates and incubated in “cell dissociation 
solution” with 2 pg/ml calcein AM for one hour. Calcein levels within the cells were measured by 
fluorescence at 520 nm using an excitation of 485 run. Linear regression was used to create standard 
curves relating RFU and cell number. pp6 cells yielded 0.157 RFU/cell (R  ̂= 0.9987), pre2 cells yielded 
0.150 RFU/cell (R  ̂= 0.9970), and E3 cells yielded 0.150 RFU/cell (R  ̂= 0.9938). Data points represent 2 
duplicates.
Differences in the invasion and migration between DU-pERV3 C3 
ppPSA/prePSA/EGSH subclones
Migration and invasion assays of DU-pERVC3ppPSA/prePSA/EGSH subclones were 
used to determine any changes induced by the different forms of PSA. The effects of 
PonA induction of PSA were also tested by comparing the difference between invasion 
and migration of 10 pM PonA induced cells with untreated control cells. DU-145 
medium containing 0.5% FBS was used as a chemoattractant through transwell 
membranes over a 24 hour period, with a coating of 0.05 mg BME/well for invasion 
assays.
Significant differences were seen in the invasive and migratory abilities of the 
different subclone types, however no significant difference was seen within each 
subclone when the cells were induced with PonA. The percentage of invasion and
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R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
migration of pp and pre subclones compared to empty vector control (E subclone) cells 
can be seen in Table 9 and Table 10. respectively.
Each of the pp6, pp9 and ppl3 subelones showed increased invasion (Figure 21) 
compared to the E2 and E3 cells, and a smaller increase in migration (Figure 22). 
regardless of the eoneentration of PonA. However, this increase was not statistically 
significant for any of the subelones, with the exception of the invasiveness of ppl3 
compared to E2 without PonA induction. Interestingly, there was variability between the 
pp subelones: pp6 showed nearly equal invasion and migration, pp9 showed a higher 
migration than invasion, and, oppositely, ppl3 showed a higher invasion than migration. 
Furthermore, the migration level of ppl3 cells was lower than E2 eells when comparing 
non-induced controls, which was in stark contrast to the significant increase in ppl3 
invasion compared to E2 invasion. This variability did not reflect the amount of PSA 
produced by each subclone, as pp6 produced ~ 4 times as much PSA as the pp9 subclone 
and ~ 3 times as much PSA as the ppl3 subclone, whereas the ppl3 subclone showed the 
highest invasion levels and the pp9 subclone showed the highest levels of migrations. In 
general, the invasion and migration of pp subclones was higher than those of the EGSH 
vector control.
Conversely, there was a large decrease in both the invasiveness (Figure 21) and 
migration (Figure 22) of the pre2 and pre? subclones as compared to the E2 and E3 
empty vector controls. These results were found to be statistically significant (p values < 
0.05), with the exception of the pre2 and pre? when compared to the migration of E2 in 
the presence of 10 pM PonA. The invasion of the pre2 subclone was as low as 28.6% of 
the E3 control and the invasion of the pre? subclone was as low as 32.2% of the E3
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control. The difference in migration was similar, with the migration of the pre2 subclone 
being as low as 62.9% compared to E2 and the pre? subclone being as much as 61.6% 
lower that E2. Although the pre? subclone produced ~ 6.5 times more PSA than the pre2 
subclone, the migration and invasion rates of each subclone were very similar. 
Interestingly, although the pre2 and pre? subclones showed the lowest invasion of all of 
the subclones, there was an increase in their invasiveness with 10 pM PonA as compared 
to the solvent control. However, a similar increase was seen in the E2 and E3 subclones.
When comparing the DU-pERV3 C3 ppPSA and prePSA subclones in both 
invasion and migration, there was an obvious and statistically significant increase of the 
pp subclones over the pre subclones (p < 0.05). These data show that ppPSA-expressing 
subclones markedly increased invasion and migration as compared to the prePSA- 
expressing subclones.
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Figure 21: Invasion o f DU-pERV3 C3 ppPSA/prePSA/EGSH cells through 0.05 mg BME/well
DU-pERV3C3ppPSA/prePSA/EGSH cells were seeded at 5X10“ cells/well in SF medium and incubated 
for 24 hours in invasion chambers with 0.05 mg BME/well. Cells were seeded along with either 10 pM 
PonA or a solvent control. The bottom wells of the invasion chambers contained DU-145 medium 
supplemented with 0.5% FBS as a chemoattractant. After 24 hours, the number of invaded cells was 
determined using the relative fluorescence units (RFU) fi-om hydrolysed calcein AM, and cell number 
determined using the appropriate standard curve. Error bars represent SEM fi-om 3 separate experiments, 
with cells seeded in duplicate.
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Figure 22: Migration of DU-pERV3 C3 ppPSA/prePSA/EGSH cells
DU-pERV3C3ppPSA/prePSAÆGSH cells were seeded at 5X10“ cells/well in SF medium and incubated 
for 24 hours in migration chambers. Cells were seeded along with either 10 pM PonA or a solvent control. 
The bottom wells of the migration chambers contained DU-145 medium supplemented with 0.5% FBS as a 
chemoattractant. After 24 hours, the number of migrated cells was determined using the relative 
fluorescence units (RFU) fi-om hydrolysed calcein AM, and cell number determined using the appropriate 
standard curve. Error bars represent SEM from 3 separate experiments, with cells seeded in duplicate.
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Table 9: Comparison of invasive capabilities of DU-pERV3 C3 ppPSA and prePSA subclones 












invasion of 10 
pM PonA E3
pp6 184.8 ±34.7 132.4 ±27.7 124.3 ± 23.4 112.5 ±23.5
pp9 208.9 ± 48.4 124.5 ±33.8 140.5 ± 32.5 105.8 ±28.7
ppl3 254.2 ± 6 3 .r 191.8 ±49.2 170.9 ±42.5 162.9 ±41.8
pre2 42.6 ± 13* 42.5 ± 11.r 28.6 ±4.9' 36.1 ±9.5 '
pre7 47.8 ± 10.7' 40.3 ± 8.0' 32.2 ± 7.2' 34.2 ± 6.8'
E2 100.0 ±20.0 100.0 ± 14.7 67.2 ± 13.4 84.9 ± 12.5
E3 148.7 ± 27.8 117.7 ±25.3 100.0 ± 18.7 100.0 ±21.5
Conditions for invasion assay are described in Figure 21. Subclones were compared 
total E2 or E3 invaded cells. Error represents percent SEM from 3 separate experiments 
duplicate. * Indicates p value < 0.05 using Student’s t-test.
as a percentage of 
with cells plated in
Table 10: Comparison of invasive capabilities of DU-pERV3 C3 ppPSA and prePSA subclones 












migration of 10 
pM PonA E3
pp6 107.4 ±41.3 99.5 ± 29.7 140.5 ± 54.0 121.1 ±36.1
pp9 139.7 ±29.0 162.8 ± 46.7 182.8 ±37.9 198.0 ±56.9
ppl3 81.9 ± 17.9 120.5 ±30.7 107.1 ±23.4 146.6 ±37.3
pre2 37.1 ±6.2 ' 42.4 ± 14.3 48.5 ±8.1* 51.6± 17.3'
pre7 32.4 ±6.9 ' 36.6 ± 10.6 42.4 ± 9.0' 44.5 ± 12.9'
E2 100.0 ±25.2 100.0 ±36.9 130.8 ±32.9 121.7 ±44.9
E3 76.4 ±6.1 82.2 ± 5.7 100.0 ±8.0 100.0 ±6.9
Conditions for migration assay are described in Figure 22. Subclones were compared 
total E2 or E3 invaded cells. Error represents percent SEM from 3 separate experiments 
duplicate. * Indicates p value < 0.05 using Student’s t-test.
as a percentage of 
with cells plated in
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Discussion
Synthesis and secretion of PSA from DU-145 cells
The DU-145 cell line was used as a model to show the direct effects of PSA expression in 
a PCa derived cell void of natural PSA production. It is known that the androgen- 
independent DU-145 cell line does not produce PSA or its encoding mRNA^^ .̂ A goal of 
this study was to produce two distinct DU-145 subclones: one that produced full length 
ppPSA to be secreted as a zymogen, and one clone that produced prePSA to be secreted 
as active PSA. DU-145 cells were transfected with plasmids containing either the full- 
length ppPSA cDNA or a truncation mutant lacking the 7 amino acid regulatory “pro” 
region, prePSA.
The first attempt at stable clone formation weis done using plasmids encoding 
PSA under the control of the CMV promoter, which induces high expression of the gene 
under its control. Upon electroporating DU-145 cells with modpSTHMppPSA, two 
clones (D-ppPSA-1 and DU-ppPSA-2) were established that expressed PSA, although 
this expression turned out to be transient. No stable clones were established using 
modpSTHMprePSA, yet transient expression from modpSTHMprePSA was seen using a 
lipofection method of transfection. This showed that the modpSTHMprePSA plasmid 
was indeed able to express PSA in DU-145 cells. It is possible that stable clones were 
not able to be isolated because the high levels of PSA expressed by these plasmids were 
unhealthy for the cells. Colonies initially growing from stable transfections with these 
plasmids often had numerous dead cells within the colony as compared to the vector 
control. Therefore, a selection for an inactivation of the CMV-promoted PSA may have 
been occurring in tandem with selection for the hygromycin resistance gene. This could
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be the reason why the D-ppPSA-1 and DU-ppPSA-2 clones soon lost expression of PSA. 
On the other hand, gene silencing after transfection is common, and the lack of stable 
PSA expression may also be due to a more generic mechanism, such as promoter 
méthylation or inactivation of the region in which the PSA gene was inserted into. 
Denmeade et al. have transfected DU-145 cells with a vector able to produce full length 
PSA using a CMV p ro mote r ' so  it would seem probable that stable transfectants using 
modpSTHMppPSA would be feasible under optimal conditions. However, the number of 
passages that DU-145 cells were able to express PSA for was not published, so it is 
possible that the clones used in those experiments also lost PSA expression over time. 
Although production of ppPSA at higher levels was most likely not toxic to the DU-145 
cells, prePSA may have been, as even short term stable clones were not observed.
To circumvent the possible toxicity of PSA production in DU-145 cells, an 
inducible expression system was used to create DU-145 subclones with PSA expression 
under the control of the insect hormone analogue PonA. DU-pERV3 C3 cells were 
selected since their stable expression of the PonA inducible transcription initiator VgEcR 
encoded by the pERV3 plasmid showed the highest levels of induction. The DU-pERV3 
C3 clone was subsequently transfected with each of the pEGSHppPSA and 
pEGSHprePSA plasmids to obtain subclones with the ability to produce ppPSA and 
prePSA, respectively. This resulted in DU-pERV3C3ppPSA cells that secreted 0.119 -  
0.461 ng PSA/ml/lO^cells/day and DU-pERV3C3prePSA cells that secreted 0.034 -  
0.218 ng PSA/ml/lO^cells/day when induced with 10 pM PonA. The PSA secreted from 
the DU-pERV3C3ppPSA subclones was in the range of 1.4 -  5.4% of LNCaP cell PSA
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production and the PSA secreted from the DU-pERV3C3prePSA subclones was in the 
range of 0.4 -  2.5% of LNCaP cell PSA production.
The level of PSA induction using 10 pM PonA ranged from 132.5 -  273.8% for 
DU-pERV3C3ppPSA subclones and from 207.6 -  280.2% for DU-pERV3C3prePSA 
subclones above those of controls. Of interest is the fact that the level of PSA production 
was relatively high in the absence of PonA. Ecdysone inducible systems are known for 
their lack of “leakiness” as compared to other inducible systems'® ,̂ so the control levels 
of PSA were expected to be much lower. As well, induction of the transiently transfected 
pEGSH-Luc plasmid in DU-pERV3 C3 cells showed high levels of relative induction by 
10 pM PonA compared to control. This is similar to what others see using this same 
plasmid system in other mammalian cells Furthermore, upon transient transfection of 
DU-pERV3 C3 ppPSA6 cells -  which showed 237% secretion of PSA when induced 
with 10 pM PonA -  with pEGSH-Luc, an induction level in luciferase activity of 2849% 
was seen (data not shown). This suggests that the VgEcR transcriptional initiator is 
operational in the ppPSA6 cells, but that the level of induction from the pEGSHppPSA 
promoter was not as high as from the pEGSH-Luc promoter. This lack of strong 
induction of PSA could be due to a number of factors. For one, the pEGSH-Luc plasmid 
was transiently transfected for the luciferase assay, whereas the pEGSHppPSA and 
pEGSHprePSA plasmids were stably transfected. There may be a difference in the 
ability of VgEcR to activate the free pEGSH-Luc plasmid in the cytoplasm as compared 
to the PSA genes that were integrated into the genome. Furthermore, the induction with 
PonA of the pEGSH-luc plasmid in the luciferase assay was done in serum-supplemented 
medium for 24 hours post transfection, whereas the induction of PSA was done over 4 -
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5 days in SF medium. The longer time was used to accumulate enough PSA in the CM 
for Western blot analysis, and SF medium was used because serum-supplemented 
medium contains too high a concentration of proteins that would “obstruct” the 10 kDa 
filter. As well, possible inhibitors from the FBS could bind and sequester PSA. Also, 
VgEcR requires natively expressed co-repressors to stop basal level transcription of the 
VgEcR controlled genes in the absence of the inducer, PonA. It is possible that the co­
repressors needed for VgEcR assisted repression of the PSA gene constructs were not 
produced in DU-145 cells in the absence of serum. Therefore, over 4 - 5  days, the 
expression may have become “leaky” and the level of induction reduced. Similarly, it is 
also possible that co-activators needed for VgEcR promoted activation in the presence of 
PonA were not produced in DU-145 cells in the absence of serum, leading to a decrease 
in transcriptional activation. Finally, 10 pM PonA was added only once at the beginning 
of the 4 -  5 day induction period, and it is unknown if components of the DU-145 
medium or factors secreted by DU-145 cells have the ability to degrade PonA over time. 
Thus, a higher level of PSA induction and expression using PonA may be feasible by 
varying experimental conditions, such as induction time, medium used, and the number 
of times PonA is added to the medium.
Molecular forms and enzymatic activity o f PSA from different sources 
In order to accurately understand the effects of PSA on PCa cell lines, the molecular 
forms of PSA in question should be understood. Two commercial preparations of PSA 
isolated from human seminal plasma, AG650 and ActPSA, were used to determine the 
effects of exogenous PSA on PCa cell lines. Each preparation presented a major band at
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29 kDa when subjected to Western blot analysis, however neither preparation appeared as 
a single band. This 29 kDa band most likely represents the enzymatically active form of 
PSA, as -80% of PSA isolated from human seminal plasma is found in the enzymatically 
active form^'. The prostate cancer cell line LNCaP is an androgen-dependant cell line 
that endogenously produces PSA. Western blot analysis of CM from this cell line 
revealed a single band for PSA at 29 kDa. This most likely represents a variety of PSA 
forms with very similar molecular weight, including active PSA and inactive forms due 
to improper N-terminal processing'®’. These include the under-processed PSA forms 
with 2 and 4 N-terminal amino acids from the pro-region remaining attached to the 
mature PSA chain, yielding an inactive enzyme'®’. Active PSA often runs on an SDS- 
PAGE at 33 kDa under reducing conditions, whereas under the non-reducing conditions -  
as used in these experiments -  mature PSA runs at a lower molecular weight closer to 29 
kDa” . The extra bands present for each AG650 and ActPSA most likely represented 
different forms of PSA, including internally cleaved, zymogen, complexed with 
inhibitors, and/or altered glycosylation. In this study, each band was recognized by the 
PSA specific monoclonal antibody A67-B/E3. This antibody has been shown to be 
highly specific for PSA, and does not cross react with hk2'®*, the most common co- 
purification contaminant with PSA*®®. AG650 included a high molecular weight band (> 
107 kDa) as well, which most likely represented an inhibitor-bound PSA, such as a 
complex with ACT. We assume that although each AG650 and ActPSA contained 
enzymatically active PSA, they also contained PSA in other forms as well as possibly 
other unidentified contaminants, such as hK2.
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Western blotting of CM from the DU-pERV3 C3 ppPSA subclones presented a 
band at 29 kDa and PSA bands from DU-pERV3 C3 prePSA subclones presented a band 
at 28 kDa. This difference corresponds well with the deletion of the 0.8 kDa “pro” 
APLILSR sequence in the prePSA gene. Although this would suggest that the major 
form of PSA found in AG650 and ActPSA was proPSA, this is not the case, as total 
protein level can affect the migration of proteins in an SDS-PAGE. Upon addition of 
ActPSA to a lane containing DU-pERV3 C3 ppPSA CM, the PSA band from the ppPSA 
subclone was present slightly higher than the 29 kDa ActPSA band, but below the 33 kDa 
ActPSA band (data not shown). Furthermore, upon addition of ActPSA to a lane 
containing DU-pERV3 C3 prePSA CM, the PSA band from the prePSA subclone was 
present at nearly the exact same weight as the 29 kDa ActPSA band (data not shown).
Each the AG650 and ActPSA isolates showed chymotrypsin-like enzymatic 
activity indicative of PSA by hydrolysis of the substrate S-2586. The activity of each 
form was also not affected to an appreciable degree by the chymotrypsin inhibitor TPCK. 
Enzymatic activity of concentrated CM from the DU-pERV3 C3 ppPSA, DU-pERV3 C3 
prePSA and DU-pERV3 C3 EGSH subclones on the substrate S-2586 was measured to 
test for the presence of PSA activity. Unfortunately, the CM from each subclone showed 
activity on the S-2586 substrate that was not abmgated by the chymotrypsin inhibitor 
TPCK, regardless of the presence of PSA. As well, the concentrations of PSA secreted 
by each subclone were below the limit of detection in this assay. Thus, the activity of 
PSA secreted from these DU-145 subclones could not be determined.
For enzymatic activity of PSA, it is critical that the cleavage site be exactly at the 
initial isoleucine of mature PSA, as cleavage on either side of this amino acid results in
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an inactive enzyme"®. This is most likely due to stabilization of the substrate binding 
pocket by the N-terminal isoleucine by interaction with an internal aspartic acid"*. This 
inhibitory “pro” region likely blocks this interaction. The objective of using 
pEGSHppPSA was to obtain an enzymatically inactive form of PSA, whereas 
pEGSHprePSA was created to allow cells to secrete active PSA. It was found by 
Denmeade et al. that PSA produced from DU-145 cells using fiill-length PSA cDNA 
under a CMV promoter does not show enzymatic activity*®̂ . This was thought to be due 
to the lack of co-secretion of an activating enzyme such as hK2” . It is therefore likely 
that the PSA produced from DU-pERV3 C3 ppPSA subclones was also in an inactive 
form, as the same coding sequence for PSA was used in the same cell line. Although the 
“pro” region was deleted in prePSA, it is possible that this form of PSA was not properly 
processed into mature PSA. Studies have shown that deletion of a “pro” regulatory 
region after a “pre” secretory sequence can lead to improper cleavage"’. However, sinde 
the N-terminus of the mature PSA sequence is an aliphatic amino acid (isoleucine) 
similar to the beginning of the “pro” sequence (alanine), it is plausible that correct 
cleavage takes place.
Future experiments to test each form of PSA for enzymatic activity could include 
zymography with a more specific substrate to PSA, such as semenogelin I or II. Also, 
reducing SDS-PAGE would show if the PSA forms produced by the cells are whole or if 
they are fragmented and being held together by disulphide bridges, which is not always 
apparent under non-reducing conditions"^. Finally, N-terminal sequencing would show 
the percentage of PSA molecules with the N-terminal isoleucine needed for activity.
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The effect of different forms o f PSA on prostate cancer cell growth 
The effects of PSA on PCa cell growth were tested over a period of five days. Firstly, 
two commercially obtained sources of PSA isolated from human seminal plasma (AG650 
and ActPSA) were added to the serum-supplemented medium of DU-145 and LNCaP 
cells to test the effects of PSA on PCa cell growth. No statistically significant effect of 
either exogenous AG650 or ActPSA -  used at concentrations from 0.5 -  2 pg/ml -  was 
seen on the growth of the DU-145 or LNCaP cell lines. This concentration range was 
chosen because it was calculated that 5X10^ LNCaP cells secrete 2.2 ± 0.9 pg/ml over a 
period of 5 days into SF medium. Although ActPSA decreased the PDT of DU-145 cells 
slightly, these results were not statistically significant. In this study, the PDT of DU-145 
cells seems to be on the decline with increasing concentrations of ActPSA, as the results 
approach significance at 2 pg/ml (p = 0.07).
Secondly, differences in the growth properties of cells secreting different forms of 
PSA were examined. Similar to the experiments using exogenous PSA sources, there 
was no statistically significant difference in cell growth between the DU-pERV3 C3 
ppPSA, DU-pERV3 C3 prePSA, or vector control cells. Although the PDT of the pp6 
and pp9 subclones was higher than that of the vector controls, the PDT of the ppl3 
subclone was not. As well, the differences in the PDT between the p6/pp9 subclones and 
vector controls were not significant, due to relatively large variance. This lack of PSA 
effect on PCa cell growth corresponds with the results of Denmeade et al., who show that 
full length ppPSA expressed in DU-145 cells does not change their growth properties*® .̂ 
Full length ppPSA expression through genetic modification also gave no difference in the
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growth properties of another androgen-independent PCa cell line, PC-3, as shown by two 
separate groups'*’ *®̂. The PSA from the CM of each the DU-145 and PC-3 cells has been 
shown to be inactive*® .̂ It is notable that prePSA produced from the DU-pERV3 C3 
prePSA cells also did not change the PDT, indicating a lack of toxicity of prePSA at the 
levels secreted.
It is possible that the lack of effects on PCa cell growth may be due to PSA 
inhibitors in the growth medium or secreted by the cells. The growth medium used for 
each cell type was supplemented with 10% FBS, which contains inhibitors for PSA, 
notably -300 pg/ml a-M ac and -40 pg/ml ACT**"*. However, Western blot analysis of 
medium conditioned for 5 days -  with various concentrations of AG650 or ActPSA -  by 
either DU-145 or LNCaP medium showed a band representing PSA at 29 kDa at intensity 
similar to the same amount of pure PSA sample (data not shown). This indicates that 
PSA was not completely complexed with either of these major inhibitors in the serum- 
supplemented medium, as PSA forms SDS-PAGE stable complexes with both a-M ac 
and ACT*’. As well, Corey et al. show that LNCaP cells secrete PSA in the free form 
into 10% FBS-supplemented medium, including the third of the PSA that is secreted in 
the active form*®’. Furthermore, Denmeade et al. show a similar lack of growth changes 
upon addition of exogenous human seminal purified PSA at concentrations from O.I -  1 
pg/ml to both DU-145 and PC-3 cells*®"*, using a growth supplemented SF medium.
Looking at the results from this study as well as those done by others, it seems 
that PSA has no effect on the growth of PCa cells. However, it has been shown that PSA 
has the ability to indirectly enhance the growth of osteoblasts**, as well as increase 
prostate stromal cell growth*®’. PSA from seminal plasma added to osteoblasts in
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culture, at concentrations as low as 25 ng/ml, is able to stimulate cell growth, presumably 
through activation of TGF-P**. Similarly, enzymatically active exogenous PSA increases 
the growth of prostate stromal cells at concentration of 100 pg/ml*®’, which is 50 times 
greater than the highest concentrations used in this study. It has also been shown that the 
enzymatic activity of PSA is responsible for the increase in growth, as the addition of 
inhibitory levels of Zn^’ abrogate the effects*®’. As well, they show that a further 
increase in growth of these cells can be caused by an enzymatic release of IGF-I from 
IGFBP-3, mediated by PSA*®’. In a separate study. Wilding et al. show that the growth 
of DU-145 cells is reduced by 25% using TGF-P at concentrations of 200 pM, and that 
this growth-reducing effect is lost after a period of 5 days**’. It would then reason that 
mature PSA activating latent TGF-P in the growth medium could decrease DU-145 cell 
growth. However, the DU-pERV3 C3 prePSA cells examined in this study may not have 
been affected by TGF-P growth reducing effects caused by this mechanism. Therefore, 
the cells would have been producing active PSA for a period of much longer than a week, 
presumably increasing the amount of active TGF-p, which the cells would become 
acclimatized to over time. LNCaP cells do not express either TGF-P RI or RII — due to 
promoter méthylation**^ -  and would not be affected adversely by an increase in TGF-P 
concentration**’. As well, it is plausible that active PSA may have a positive effect on 
PCa cell growth, as it has been shown that active PSA can degrade both IGFBP-3 and 
IGFBP-4*’ so that IGF-I is freed to interact with surface receptors. It has been shown 
that LNCaP cell growth is unaffected by IGF-I, even though these cells secrete this 
growth factor**’. DU-145 cells do not produce IGF-I, however they do produce IGFBP- 
2/-3/-4Z-6***. Also, DU-145 cells have also been shown to increase their DNA synthesis
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upon addition of IGF-I to the growth medium*’. Therefore, it is reasonable to assume 
that if active PSA were to cleave both IGFBP-3 and IGFBP-4, releasing IGF-I from the 
FBS, the growth of DU-145 cells could increase. It is possible that PSA can have a 
positive or negative effect on DU-145 cell growth through IGF-I and TGF-p respectively. 
The concentrations of exogenous PSA possibly need to be higher.
The effect o f different forms o f PSA on in  v i t r o  prostate cancer cell 
migration and invasion
To test the migratory changes induced by PSA, DU-145 and LNCaP cells were allowed 
to traverse a transwell membrane. Invasive changes induced by PSA were studied using 
the same transwell membrane coated with a simulated basement membrane. No 
statistically significant change in migration or invasion was seen for the DU-145 cells 
upon addition of AG650 or ActPSA at concentrations from 0.5 -  5 pg/ml. Notably, there 
was a consistent (if not statistically significant) decrease in the invasion of DU-145 cells 
through 0.05 mg/ml BME using both 0.5 or 10% FBS as a chemoattractant, with 
concentrations of ActPSA ranging from 0.5 -  5 pg/ml. A decrease in invasion was not 
seen when using AG650 PSA, however this preparation of PSA was only stated to be 
90% pure by the manufacturer, so it is possible that any effects caused by PSA may have 
been counteracted by unknown contaminants. Unfortunately, the invasion and migration 
of LNCaP cells occurred at levels too low to be accurately quantified using the 
experimental parameters employed in this study. PSA-producing subclones derived from 
DU-145 cells were also assayed for migration and invasion. The DU-pERV3 C3 ppPSA 
subclones showed a moderate increase in invasion and a slight increase in migration over
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the vector control DU-pERV3 C3 pEGSH cells. Conversely, the DU-pERV3 C3 prePSA 
cells showed a statistically significant decrease in both migration and invasion compared 
to the vector control cells. Interestingly, DU-pERV3 C3 ppPSA subclones expressing 
higher levels of ppPSA (i.e. pp6) did not show consistently increased invasion or 
migration over subclones with lower ppPSA expression (i.e. pp9). Similarly, DU-pERV3 
C3 prePSA subclones expressing higher levels of prePSA (i.e. pre7) did not show 
consistently increased invasion or migration over prePSA subclones with lower ppPSA 
expression (i.e. pre2). As well, no trend in invasion or migration was seen through 
increasing the level of PSA produced by PonA induction. Therefore, what seems to be 
changing the invasion of the cells appears to be a phenotype change, since differences in 
cellular invasion and migration do not correspond directly with the amount of PSA 
produced, only the form.
The results found in this study are similar to those found by Veveris-Lowe et al."*’. 
They genetically modified the androgen-independent PC-3 cell line with the ability to 
produce ppPSA and these cells show an increase in migration but not invasion"*’. This 
increase in migration was reasoned to be caused by an EMT, as the cells expressed lower 
E-cadherin levels and higher vimentin levels than the vector controls**®. Although the 
activity of PSA has not been determined in those experiments, Denmeade et al. found that 
PSA secreted by PC-3 cells (genetically modified to produce ppPSA) is inactive*®"*. 
Thus, it is likely that the form of PSA produced in the Veveris-Lowe experiments is also 
inactive. Since inactive PSA is produced by PC-3 cells, and the cells undergo an EMT, 
there seems to be an effect of PSA in the PC-3 cells that is not due to its proteolytic 
activity. This is interesting, as these results are similar to what was seen for the DU-
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pERV3 C3 ppPSA cells in this study, which were also transfected with a ppPSA- 
producing vector. However, an increase in invasion was also seen for the DU-pERV3 C3 
ppPSA cells as compared to controls, and a less pronounced increase in migration. Both 
native DU-145 and PC-3 cells express vimentin*’®, however, vimentin expression is 
upregulated in PC-3 cells transfected with ppPSA"*’. As well, E-cadherin is expressed in 
both cell types, and expression of this cell-cell adhesion protein is almost completely lost 
in PC-3 cells transfected with ppPSA"*’. To assess if there was an EMT in the DU- 
pERV3 C3 ppPSA subclones, it would be useful to determine the levels of vimentin and 
E-cadherin. The increase in cellular migration and invasion by the ppPSA expressing 
cells in this study further supports the theory that PSA causes cellular effects independent 
of proteolytic activity.
The data obtained in this study also suggest that enzymatically active PSA 
decreased cellular invasion, both from an exogenous source, and -  more prominently 
when prePSA was produced by the cells. This is the opposite to what was found by 
others in previous experiments testing invasion of LNCaP cells. Although the invasion 
and migration of LNCaP cells was not quantifiable in this study, it has been found by 
Webber et al. that if the activity of PSA is blocked using monoclonal antibodies against 
the active site, LNCaP cells show a decreased invasion"*’. Similar results have been seen 
by Ishii et al., who used antibodies against active PSA or the addition of inhibitory levels 
of Zn^’, and show decreased in vitro invasiveness of LNCaP cells"*̂ . Yet under the same 
conditions, PC-3 cells -  which do not produce PSA — do not show a change in invasion"* .̂ 
Each of these examples points to active PSA contributing to the invasive potential of 
LNCaP cells.
112
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
It is possible that some of the increasing effects on LNCaP cell invasion thought 
to be due to PSA are actually due to hK2. hK2 has the ability to activate the zymogen 
forms of both PSA, uPA and can inactivate PAI-1*’*. As well, hK2 can degrade 
fibronectin and IGFBP-2/-3/-4/-5"". At first, some of the enzymatic activities of hK2 
were actually thought to be contributed by PSA, however, Frenette et al. show that it is 
actually hK2 which is responsible for the activation of uPA*®®. This is due to the fact that 
hK2 and PSA (hK3) are about 80% homologous to each other on the amino acid level*’*, 
and hK2 is easily (and accidentally) co-purified with PSA*®®. Ishii et al. admit in their 
paper that the decrease in LNCaP invasion might actually be due to hK2 and not PSA, as 
Zn”  inhibits both PSA and hK2, and the antibody they used against PSA might also cross 
react with hK2"*̂ . However, it is unlikely that the same is true for the LNCaP invasion 
experiments done by Webber et al., as they used the anti-PSA antibody ER-PR8 (M 
0750) to block invasion"*’. When studied in an international panel analyzing numerous 
anti-PSA antibodies for epitope localization, enzymatic activity inhibition, and cross­
reactivity, ER-PR8 did not show cross reactivity with hK2, and inhibited PSA enzymatic 
activity by -50%*®*. Nevertheless, this does not necessarily mean that it is the enzymatic 
activity of PSA that is responsible for the increase in invasion, as this antibody may also 
block protein-receptor interactions of PSA through steric hindrance. This is a plausible 
explanation, as LNCaP cells have been shown to mainly secrete enzymatically inactive 
forms of PSA, constituting at least 2/3 of the total PSA in LNCaP CM*®’’*®’’*” . The 
effects of PSA upregulation or the addition of exogenous PSA on LNCaP invasion and 
migration has not been studied. Since decreasing the activity of PSA lowers the invasive 
potential of LNCaP calls, it would be interesting to see if exogenous active PSA would
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increase LNCaP cell invasion. This would help prove that enzymatically active PSA 
does assist in the invasion of LNCaP cells.
Unexpectedly, when using 0.5% FBS, the migration of all cells tested was often 
similar to or only slightly less than the invasion. This difference may have been due to 
the low adherence of the cells to the cell-transwell membrane under the low FBS 
conditions. When seeding DU-145 cells in cell culture plates using 0.5% FBS- 
supplemented medium, they take longer to adhere than when using 10% FBS- 
supplemented medium (data not shown). It is likely that DU-145 cells (and subclones) 
more readily adhere to the BME coating than to the transwell membrane, as BME 
simulates a natural substrate for epithelial cells. Although the cells must first degrade the 
BME before migrating through the transwell membrane in the invasion assay, this may 
happen at a more rapid pace than cells adhering to the transwell membranes in the 
absence of BME in the migration assays. Furthermore, as the cells degrade the BME, 
chemotactic fragments may be revealed from cryptic sites on BME molecules, ftirther 
increasing the invasive potential of the invasive cells over that of those migrating through 
the membrane alone.
The reasons why prePSA produced by the DU-pERV3 C3 prePSA cells would 
decrease both invasion and migration to such a striking degree is less clear, and there are 
numerous possible rationales. Firstly, PSA has been shown to increase the invasion of 
LNCaP cells, not DU-145 cells. LNCaP cells are androgen-sensitive, whereas DU-145 
cells are androgen-independent, so it is likely that if there are any cellular effects due to 
PSA activity on invasion or migration that they may have different effects on each cell 
type. Furthermore, the experiments in this study used FBS-supplemented medium as a
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chemoattractant, yet the previous studies testing LNCaP invasion used NIH-3T3 CM"*’ 
and SF medium (with the BM itself presumably acting as the chemoattractant)"* .̂ This 
could lead to different factors being activated or degraded by active PSA. Since both the 
invasion and migration of DU-pERV3 C3 prePSA cells was decreased compared to 
controls, it is unlikely that the degradation of BM components mediated by active PSA 
had much effect on decreasing cellular invasion of this cell type. It seems probable from 
these results that there is a competing effect between the actions of proPSA and mature 
PSA on cancer invasion, with proPSA having receptor-mediated effects and mature PSA 
having enzymatic effects. As opposite effects were seen from the ppPSA and prePSA 
producing cells, it seems likely that there is some proteolytic activity that causes the large 
differences in invasion and migration. Such activity could include the cleavage or 
proteinase-activated receptors (PARs) being responsible for the effects mediated by 
prePSA"*"*, however this is just speculation. Finally, on the other hand, there is the 
possibility that the PSA secreted by DU-pERV3 C3 prePSA cells was not proteolytically 
active, ai • that the decrease in migration and invasion was due to protein-protein 
interactions. In contrast, the PSA produced by DU-pERV3 C3 ppPSA cells may become 
activated in the invasion assays by some factor within the BME. It has been shown that 
reconstitution of Matrigel (a similar in â*ro BM simulate to BME) can activate 
plasminogen to plasmin*” , so it is reasonable to assume there may be an activated 
protease in the BME that could proteolytically activate ppPSA.
There are multiple steps that can be taken to further clarify the effects of the 
different forms of PSA through the use of the DU-pERV3 C3 ppPSA and DU-pERV3 C3 
prePSA subclones. For one, the invasion and migration time could be increased to 48
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hours to allow the possibility of more significant differences between the clones, as well 
as allow for quantifiable levels of invasion/migration for the LNCaP cell line. The 
original 24 hours was chosen because the number of DU-145 cells migrating towards 
10% FBS was above the range of accurate quantification at 24 hours, and it was expected 
that a longer time period of invasion would show the same results. With the 
concentration of FBS decreased to 0.5%, the migration was significantly reduced, 
approximately to the level of invasion. Furthermore, since PSA is able to affect the 
growth of prostate stromal cells*®’, this might have an affect on in vivo invasion of cancer 
cells, as PSA might stimulate the release of chemotactic factors from prostate stromal 
cells. It would be interesting to plate DU-pERV3 C3 ppPSA and DU-pERV3 C3 prePSA 
cells in the top of invasion chamber, with prostate stromal cells in the bottom to 
determine effects more similar to in vivo conditions. Finally, the secreted forms of PSA 
in the medium of DU-pERV3 C3 ppPSA and DU-pERV3 C3 prePSA cells still need to 
be determined. CM firom each of these cell types could also be used in invasion and 
migration assays with the native DU-145 cells to further prove the effects of each PSA 
type. There was an obvious difference in invasion seen between prePSA and ppPSA 
subclones as well as empty vector control cells, showing that prePSA had some effect on 
the cancer cells different than seen from the expression of full length ppPSA.
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Conclusion
The main goal of this study was to determine the effect that different forms of PSA had 
on prostate cancer cellular invasion. To a point, this was accomplished. The experiments 
in this study show that exogenous active PSA was able to decrease the invasion of DU- 
145 cells. It was also found that DU-145 subclones genetically modified to produce 
ppPSA had increased invasive potential, while DU-145 subclones genetically modified to 
produce prePSA had greatly decreased invasive potential. Although the form of PSA 
secreted from the prePSA producing cells was not fully characterized, it is likely that this 
was an active form of PSA. The cells producing prePSA also showed a large decrease in 
migration, and this most likely contributed heavily to their lack of invasiveness.
We conclude here that active PSA decreased the invasive potential of DU-145 
prostate cancer cells, while the production of inactive PSA increases their invasive 
potential. This conclusion seems to conflict with the idea that active PSA increases 
invasion of prostate cancer cells, as found by others. However, most of the work done 
previously concerning PSA and invasion was on other prostate cancer cell lines, so it 
appears that the actions of PSA on prostate cancer cell invasion in vitro are not 
straightforward. The effect of PSA may be different for androgen-dependent prostate 
cancer cell lines than for androgen-independent cells.
To truly understand the effects that each form of PSA had on invasion, each form 
will have to be full characterized. If the ppPSA producing cells produce mainly or 
entirely inactive PSA and the prePSA producing cells produce mainly inactive PSA, 
these DU-145 subclones could prove important in differentiating any number of effects 
caused by zymogen PSA or the enzymatically active form. As well, in vivo studies
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introducing the ppPSA and prePSA-producing DU-145 subclones into mice would 
provide valuable insight into the effect of each PSA form on tumour invasion. Since PSA 
is used prevalently as a diagnostic tool, it would be useful to determine if active PSA 
benefits, hinders, or is not involved at all in tumour invasion.
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